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Transcription factors represent one of the primary determinants of gene expression 
changes and phenotypic modulation during dynamic processes in multi-cellular organisms. 
This includes processes as diverse and important as; development, differentiation and 
oncogenesis. Traditional scientific approaches rely on introducing one modification/change 
at a time and seeing how this impacts a specific outcome. As such, when probing the role 
from over-expression of a target gene, information can be acquired by over-expressing 
cDNA derived from a protein encoding gene. However such approaches remove much of 
the vital biological context provided by the local epigenetic context as well as the role of 
un-translated regions in modulating the stability, expression and localisation of 
transcripts/proteins.  
 
Conversely when over-expressing a transcription factor known to target the promoter of a 
gene of interest, it can become extremely challenging to narrow down the contribution to 
phenotype caused by the gene of interest being over-expressed, compared to the multiple 
other gene promoters bound by any one transcription factor. As such the generation of 
synthetic transcription factors providing predictable, stable binding to a specific locus, with 
minimal off-target binding provides powerful capabilities for exploration and manipulation 
of transcriptional networks. To this end, RNA guided homing endonuclease CRISPR systems 
have been adapted, through the generation of catalytically inactive variants, to serve as 
easily targetable DNA binding domains. These can be used to recruit transactivation 
domains to targeted promoters and increase expression for the target gene. 
 
In this work we validate and characterise synthetic transcription factors adapted from 
Cas12a/Cpf1 derived from three different species. Cas12a, unlike Cas9 possesses the ability 
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to process its crRNA array through native RNase activity and uses the short crRNAs 
generated for the targeting of multiple unique loci. This means that designing and 
constructing genetic constructs for generating guide RNAs becomes cheaper and simpler 
and furthermore, the reduced size of DNA required for targeting provides benefits when 
considering packaging size constraints, such as with the AAV virus. We go on to further 
characterise the capabilities and limitations of these crRNA arrays for a variant derived 
from Francisella novicida - FnCas12a. This variant, unlike the more commonly utilised 
variants derived from Acidaminococcus sp BV3L6 (AsCas12a) and Lachnospiraceae 
bacterium ND2006 (LbCas12a), requires a shorter characterised PAM sequence ‘TTV’ for 
targeting, providing a comparable targeting density to the widely used Streptococcus 
pyogenes derived SpCas9 platforms. Our results open up dFnCas12a as a potential new 
gold standard for homing endonuclease derived scaffolds for recruiting diverse effector 
domains, preserving the best qualities of the SpCas9 system, whilst incorporating added 




Almost all of the cells in our body share the same DNA sequence with the same genes and 
yet they come in various shapes, sizes and functions, helping to make your heart beat, or 
filter toxins out of your blood. Your genes each produce unique proteins that help define 
what a cell looks like, how it functions and interacts with its neighbours. It is the differences 
in expression of these genes and the proteins they produce that explains the extraordinary 
diversity of cells we see. 
 
My work focusses on trying to create more effective tools to cause over-expression of 
multiple chosen genes.  This is very useful for scientists trying to better understand how 
these genes work together to cause changes in the cell. Alternatively for cell therapies, 
where we need to deliver a specific cell type to help repair an organ, this tool can allow us 
to take cells from our skin and over-express several genes to change the cell from one type 
to another.  
 
Finally with genetic conditions such as sickle cell anaemia, the version of the oxygen 
carrying protein ‘haemoglobin’ produced by adults is defective, but this can be fixed by 
increasing expression of a different version that is only well expressed until we are 4 
months old. This is a relatively simple solution to a well known genetic condition, however 
many genetic conditions are caused by problems associated with multiple genes. The tool I 
have developed in the following work is especially well suited for specifically interacting 
with multiple genes and causing their over-expression. We have shown the upregulation of 
multiple genes with targeting achieved from a single DNA construct. Furthermore we have 
provided information on the capabilities and limitations of targeting, which can help aid 
biological researchers and potentially clinical researchers. 
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It is one thing to better understand the complicated causes of genetic conditions, it is quite 
another to use this information to try and fix debilitating conditions. The tool I have been 
working on should be able to help address both of these. First by allowing us to more easily 
change expression of multiple chosen genes for cells in a dish and gaining insight by seeing 
how this impacts the cells and whether we see desirable changes. Secondly after rigorous 
testing this tool could be used alongside the information we have learned to try and tackle 
what are currently incurable, debilitating genetic conditions. 
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Chapter 1 Introduction 
 
1.1 Synthetic transcription factors 
Transcription factors are found in both prokaryotes and eukaryotes and help coordinate 
transcriptional regulation, by increasing the transcription rate of a physically proximal gene 
through the recruitment of RNA polymerase to an associated promoter. Transcription 
factors typically target multiple loci in a context specific fashion (Wang, 2005) (Teif and 
Rippe, 2010), with binding to a locus being driven by chromosomal accessibility and the 
presence of the ‘consensus sequence’ within DNA. Unlike those employed for synthetic 
transcription factors, the DNA binding domains of natural transcription factors typically 
have highly specific binding to only 5-8 nucleotides within a short stretch of DNA, alongside 
less specific binding to surrounding nucleotides. While this provides flexibility within an 
evolutionary context, it creates challenges for researchers wishing to induce specific effects 
at targeted loci in a controlled fashion, creating demand for more precise and predictable 
binding domains. As such, researchers have explored synthetic transcription factors as a 
means of specifically transactivating target genes. 
 
One of the first synthetic transcription factors to be successfully developed utilised zinc-
fingers (Liu et al., 1997) (Figure 1-1A), with the design centring around zinc finger motifs 
naturally found in many transcription factors. Initially zinc finger approaches seemed very 
promising, with early work presuming a simple ‘mix and match’ of zinc fingers individually 
designed with specificity for each of the DNA codons, thereby requiring only 64 
independent zinc-fingers to enable specific coverage of any DNA sequence (Pavletich and 
Pabo, 1991). There were, however, multiple caveats. Not only was the construction very 
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laborious and only carried out by specialised labs, but perhaps the biggest limitation was 
the cross-recognition of adjacent zinc fingers. This means that the binding capability of 
individual zinc finger motifs are  
dependent on the adjacent zinc finger motifs, complicating the design and necessitating 
experimental screening of binding. As such, this technique has rapidly been outpaced by 
more recent techniques mentioned below.  
 
In the following years a new approach utilising ‘transcription activator-like effectors’ 
(TALEs) was discovered. TALEs are a virulence factor produced by Xanthomonas (a 
proteobacteria that causes disease in plants), which mimics eukaryotic transcription factors 
to reprogram host cells (Zhang et al., 2000). Their targeting capabilities were first 
characterised in 2009, (Boch et al., 2009), and the same team also showed that TALEs could 
be used to construct artificial DNA binding proteins capable of targeting any desired 
sequence. The TALEs DNA binding domain is often composed of tandem repeats of 34 
amino acid modules, each possessing variability at positions 12 and 13. It is these ‘repeat 
variable di-residues’ (RVDs) that target a specific base of the DNA (Figure 1-1B) (Deng et al., 
2012) (Morbitzer et al., 2010)(Streubel et al., 2012). These RVD repeats can be 5.5 to 34.5 
repeats long with the final 0.5 repeat contributing to the correct binding of the last 
nucleotide target (Boch et al., 2009). The TALE system offers unique advantages over the 
Zinc finger approaches, as each module is able to bind independently of the surrounding 
modules, meaning that TALEs could be predictably designed.  
 
The following year, Morbitzer et al. demonstrated that TALEs could be used to generate 
synthetic transcription factors (Morbitzer et al., 2010). In particular, they showed that by 
changing the RVD’s within the TALE-Avrbs3 fusion protein, they were able to target the 
protein to induce robust up-regulation of the Bs4S gene, measured using semiquantitative 
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RT-PCR. Since then, TALE based synthetic transcription factors have been employed for a 
number of uses including the treatment of genetic conditions (Chapdelaine et al., 2013), 
reprogramming mouse fibroblasts to pluripotency (Gao et al., 2013) and regulating 
synthetic gene circuits (Garg et al., 2012). 
 
 
Figure 1-1 - Evolution of synthetic transcription factors 
Diagrammatic representation of the zinc finger, TALE and Cas9 derived synthetic transcription 
factors/transcriptional repressors. For zinc finger-based synthetic transcription factors, each zinc 
finger is able to recognise 3 nucleotides, dependent upon the adjacent zinc fingers. For TALE-based 
synthetic transcription factors, each RVD repeat can bind and recognise a single nucleotide 
independent of adjacent repeat variable di-residues (RVD) repeats. For Cas9-based synthetic 
transcription factors, the dCas9-effector protein can be guided to a locus, as long as an adjacent 







































One of the most transformative innovations for DNA binding modules and synthetic 
transcription factors has been the discovery of the clustered regularly interspaced short 
palindromic repeats (CRISPR) Cas9 system, and its subsequent adaptation for use as a 
synthetic transcription factor. CRISPR/Cas9 evolved as a form of adaptive immunity, which 
can process and integrate foreign DNA into the host genome and use the newly produced 
transcripts as a targeting mechanism to specifically cleave the foreign DNA (Figure 1-2). 
 
The first step of this process, known as adaptation, relies upon the processing of foreign 
DNA by Cas1 and Cas2 to produce a short fragment of DNA that is subsequently inserted 
into the CRISPR array (Yosef et al., 2012) (Figure 1-2). This (often viral) ‘protospacer’ DNA 
must possess a protospacer adjacent motif (PAM), adjacent to the protospacer, that can 
then be recognised by the Cas9 protein in down-stream cleavage reactions. However this 
PAM sequence is not incorporated into the crRNA array to prevent self-targeting (Horvath 
et al., 2008). In the second stage – CRISPR RNA (crRNA) processing, the precursor crRNA 
array is transcribed and processed into mature crRNA. First trans-activating crRNA 
(tracrRNA) hybridises with the direct repeats within the crRNA array, Cas9 and RNaseIII can 
subsequently process the crRNA arrays into independent guide RNAs (gRNA). In the final 
interference step, the gRNA combine with the Cas9 protein, to enable targeting of foreign 
DNA. When the mature Cas9/gRNA complex interacts with the appropriate PAM sequence 
(‘NGG’ for Spcas9) the DNA is melted and if the adjacent protospacer sequence is 
complementary to the spacer sequence within the crRNA then the Cas9 binds and induces 
a blunt ended double strand cleavage of the target DNA (Figure 1-2). CRISPR/Cas9 is a Class 




Whilst the direct repeats, that are characteristic of CRISPR were initially identified in 1987 
(Ishino et al., 1987), it was only in 2007 that these repeats were characterised to play a role 
in bacterial defence against viruses (Barrangou et al., 2007). Subsequent work showed that 
Cas9 was the only cas gene essential for CRISPR-encoded interference when expressed in 
Escherichia coli (E. coli) (Sapranauskas et al., 2011). In 2012 the promise of the CRISPR 
system and in particular Cas9 was highlighted by Jinek and colleagues (Jinek et al., 2012). 
The team showed that Cas9 could be targeted to specific DNA sequences using only a single 
guide RNA, composed of a crRNA-tracrRNA fusion, as opposed to the two separate crRNA 
and tracrRNA molecules normally required for successful targeting in bacteria. Initially, this 
innovation represented the capability to easily construct gRNAs to target the wild-type 
Cas9 endonuclease to desired chromosomal loci, inducing double strand cleavage. This 
enabled either the formation of indel mutations through inefficient non-homologous end 
joining (NHEJ) in human cells (Mali et al., 2013), or the targeted insertion of genetic 
material using a homologous repair template through homology directed repair (HDR) in 
mouse cells (Yang et al., 2013). 
 
Jinek et al. also showed that introducing single amino acid substitutions in the two Cas9 
nuclease domains HNH and RuvC lead to their inactivation (Jinek et al., 2012). This 
catalytically inactive “dead Cas9” (dCas9) maintained the capability to bind DNA but no 
longer induced cleavage (Figure 1-3A) and could serve as a simple RNA-guided DNA binding 









Figure 1-2. - Representation of CRISPR/Cas9 adaptive immunity 
In stage 1, invading DNA is processed by the Cas1-Cas2 complex. A processed spacer 
sequence can then be incorporated between two direct repeats within a crRNA array. In 
stage 2 the crRNA array is transcribed and processed, with tracrRNA hybridising to the 
direct repeats, enabling processing by RNaseIII and Cas9 to generate individual gRNAs (with 
one spacer sequence containing crRNA per gRNA). In the final stage, the gRNA can complex 
with Cas9, the Cas9 protein can recognise and melt a protospacer-adjacent motif (PAM) 
sequence and if the spacer sequence is able to hybridise with the melted DNA, Cas9 





























1.3 CRISPR/Cas9 transcriptional repressors 
One of the early observations for the dCas9 protein was its ability to induce transcriptional 
repression in bacterial and mammalian cells by providing a steric block to the processive 
RNA polymerase (Gilbert et al., 2013)(Qi et al., 2013). However, while this system allowed 
approximately 1000 fold silencing in E.coli, only approximately 2 fold repression was 
achieved in mammalian cells. As such researchers generated fusion proteins to act as 
transcriptional repressors. Gilbert and colleagues tested three previously characterised 
repressor domains using the dCas9 scaffold; the Krüppel associated box (KRAB) (Margolin 
et al., 1994), the CS domain from HP1α (Hathaway et al., 2012) and the WPRW domain 
from Hes1 (Fisher et al., 1996). The team saw that the KRAB-dCas9 fusion protein was the 
most effective at repression, inducing 15-fold repression when targeted to GFP expressed 
from a constitutive promoter in HEK293 cells that had been delivered by lentivirus 14 days 
prior (Gilbert et al., 2013). The capabilities of transcriptional repressors such as dCas9-KRAB 
make for very powerful tools when combined with synthetic transcription factors, by 
enabling simultaneous transactivation and repression of unique genes, enabling interaction 
with gene networks that frequently incorporate complicated feedback loops, relying on 
repression as well as activation. 
 
1.4 CRISPR/Cas9 synthetic transcription factors 
Within a year multiple groups showed the utility of this scaffold, attaching and testing 
activator domains such as the VP16 tetramer - VP64 (Maeder et al., 2013a) and p65 
(Gilbert et al., 2013) (Figure 1-3B). Gilbert and colleagues separately fused VP64 and p65 
activation domains to dCas9 proteins, which were subsequently targeted to the upstream 
activation sequence of the Gal4UAS-GFP reporter. When measuring GFP levels two days 
post transfection, the team saw a 25-fold up regulation of GFP for the dCas9-VP64 fusion 
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protein relative to a negative control with no targeting gRNA. They also observed a 12-fold 
up regulation of GFP for the dCas9-p65 fusion protein relative to a negative control with no 
targeting gRNA. They utilised a similar GFP reporter strategy for analysing repression and 
tested the effect of the dCas9-KRAB fusion protein when targeted to multiple different loci 
within an SV40 promoter driving expression of a GFP reporter gene. They observed up to a 
15-fold repression of GFP expression when targeting the transcription start site. 
 
An important observation Maeder and colleagues noticed when inducing activation of the 
VEGFA and NTF3 genes, was improved transactivation when targeting multiple rather than 
single gRNAs to the respective promoter. They observed that the up-regulation of 
expression induced using multiple gRNAs was significantly higher than predicted from the 
additive effects of all the single gRNAs acting independently. This was in agreement with 
what had been learnt from earlier TALE-based approaches (Maeder et al., 2013b). It is 
important to note that, whilst more effective, the use of multiple gRNAs to target the same 
locus would be less desirable for projects where many loci are targeted, due to the 
increased number of gRNAs and associated challenges for design and delivery. In part to 
address this problem, subsequent work has focussed on generating synthetic transcription 
factors possessing improved activity. 
 
1.5 More powerful effectors 
Work focussing on generating stronger and more reliable transcriptional activators has led 
to a rapid expansion of verified dCas9 transactivators, whether they rely on previously 
characterised domains (Maeder et al., 2013a) (Gilbert et al., 2013) or trial alternative 
variations such as the VPR domain (Chavez et al., 2015). The VPR domain is a three part 
effector comprised of the transactivator domains; VP64, p65 and Rta connected by flexible 
glycine-serine linkers, and fused to dCas9 by such a linker (Figure 1-3B). This effector 
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allowed greater increases in expression of a range of genes when compared to VP64 alone, 
and as of writing remains the best single component activator directly coupled to dCas9. 
Chavez et al. observed a 22- to 320-fold improved activation of targeted genes relative to 
the dCas9-VP64 fusion protein when relative RNA expression was analysed. Furthermore, 
the team demonstrated that the approach was suitable and effective for multiplexing, with 
the genes MIAT, NEUROD1, ASCL1 and RHOXF2 showing simultaneously significantly higher 
gene expression for all tested genes relative to a dCas9-VP64 control. One caveat of the 
study was the group’s reliance on 3-4 gRNAs per promoter to induce up-regulation. Further 
testing using only one gRNA per targeted promoter could help demonstrate the broader 
utility or limitations of this effector. 
 
Other approaches have also been devised in an effort to maximise expression, with more 
complex two component activators such as the SunTag (Tanenbaum et al., 2014) and SAM 
systems (Konermann et al., 2015) being developed. The SunTag approach relies on fusing a 
tandem array of peptides to the dCas9 protein (Figure 1-3C). These peptides can be used to 
recruit single-chain variable fragments, engineered antibody fragments, which are fused to 
the VP64 transactivator. Using this approach, one dCas9 protein can recruit up to 24 copies 
of VP64, reliably increasing activation far beyond single copy variants. This in turn 
translated to not only a significant up-regulation of the chemokine receptor CXCR4 gene, 
but they observed that this up-regulation resulted in a corresponding change in migration 
of the K562 cells used in the study. The cells showed a less than 2-fold increase in migration 
when the gene expression was up-regulated using dCas9-VP64 compared to over 15-fold 




A further approach, the synergistic activation mediator (SAM) system (Figure 1-3C), also 
relies upon recruitment of multiple copies of the activators p65 and HSF1, whilst also 
tethering a VP64 domain fused directly to the dCas9. This system however utilises RNA-
aptamer based recruitment, whereby the gRNA is designed to incorporate two MS2 hairpin 
loops within the tetraloop and stem-loop 2 (Konermann et al., 2015). Konermann and 
colleagues went on to show for 10 out of the 12 genes tested the SAM system showed 
stronger activation than pools of 8 single gRNAs used in conjunction with dCas9-VP64. The 
SAM system also enables gRNA dependent orthogonality, as changing the aptamer 
incorporated into the gRNAs enables recruitment of alternative aptamer binding proteins, 
which in turn can be tethered to antagonistic effectors, as later shown by Truong et al. 
where they showed simultaneous transactivation and repression (Truong et al., 2019). 
 
When comparing the relative strengths and weaknesses of the previous approaches, it is 
important to highlight that whilst two component systems such as SunTag and SAM can 
offer increased recruitment of transactivation domains or intrinsic orthogonality, 
respectively, the necessity for co-delivery of secondary effectors (either linked to antibody 





Figure 1-3 - Classes of Cas9-based synthetic transcription factors 
 A) Wild type Cas9 can be targeted to a locus by a gRNA to induce a double strand break. 
Through two amino acid substitutions in the HNH and RuvC domains, cleavage can be 
abolished creating a RNA guided DNA binding domain (dCas9). B) Single domain or multi-
domain effectors can be fused to dCas9, to enable targeted transactivation or repression of 
adjacent genes using a single fusion protein. C) Multi-component approaches rely on the 
recruitment of secondary proteins to either recognition peptides (SunTag system) or to 

































With the exception of the SAM system, current approaches rely on effectors fused or 
recruited directly to the dCas9 protein. This means that when utilising the same dCas9 
variant, only one effector, such as an activator or a repressor, can be utilised within a cell 
as all targeting gRNAs will interact with the dCas9 irrespective of the fused effector 
domain. This creates some important challenges for areas such as cellular reprogramming, 
where complex gene networks rely on negative as well as positive feedback loops (which 
might require repressors and activators, respectively) and the ability to inhibit gene 
expression may prove just as important as the ability to activate master transcription 
factors. As such, the need has arisen for orthogonal systems, which enable the 
simultaneous targeting of a synthetic transcription factor to a subset of loci and the 
targeting of a transcriptional repressor to a different subset of loci, without cross-talk 
occurring. This need has been met by a number of strategies. 
 
One such strategy relies upon the intrinsic orthogonality of the TALEs, which function in a 
gRNA independent way. However, utilising TALEs leads to the previously described 
limitations, where individual proteins must be designed and generated for each locus to be 
targeted. An alternative strategy that has been developed relies upon the subtle 
differences between the Cas9 variants found in nature and the orthogonality of their 
respective gRNAs. For example, Esvelt and colleagues showed that three Cas9 variants, 
from Streptococcus pyogenes (dSpCas9), Streptococcus thermophilus (dStCas9) and 
Neisseria meningitidis (dNmCas9), showed high orthogonality relative to one another 
(Esvelt et al., 2013). In particular when  
 
 Further work by Gao and collegues showed that simultaneous activation and repression of 
two different reporter genes could be achieved when employing a dSpCas9-KRAB repressor 
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alongside an Staphylococcus aureus dSaCas9-VPR synthetic transcription factor (Gao et al., 
2016). However, there is a reason why S. pyogenes derived Cas9 is most consistently used 
and favoured for targeting, as it possesses a very short PAM sequence ‘NGG’, allowing 
targeting on average every 8bp of a genome when targeting either strand. This contrasts 
with the PAM sequences seen for Staphylococcus aureus (SaCas9), Neisseria meningitidis 
(NmCas9) and Streptococcus thermophilus (StCas9) with PAM sequences; ‘NNGRRT’, 
‘NNNNGATT’ and ‘NNAGAAW’ enabling targeting every 32, 128 and 256 bp respectively. 
Whilst such limitations may be acceptable for some applications, they can pose a problem 
for targeting multiple promoter regions with synthetic transcription factors, where 
positioning can be essential, with evidence showing an optimal window of 50 to 400bp 
upstream of transcription start sites  (Gilbert et al., 2014) 
 Furthermore, targeting limitations can provide a particular challenge when targeting 
promoters with several gRNAs, which has been demonstrated to be more effective in 
activation than single gRNA approaches (Maeder et al., 2013a) (Perez-Pinera et al., 2013). 
 
1.7 Chromatin editors 
Alongside the transcriptome, researchers have also explored modification of the 
epigenome – the semi-heritable chemical changes to genomic DNA and associated 
histones. Our understanding of the roles of specific histone and DNA modifications is only 
increasing with time (Snowden et al., 2002) (Costello et al., 2013) and large scale projects 
are continuing to characterise epigenomes from multiple cell types (Roadmap Epigenomics 
Consortium et al., 2015). Global epigenetic modifications through the delivery of chemicals 
(Halby et al., 2012) or over-expression/miRNA knockdown of native epigenetic modifiers 
(Luco et al., 2010) have enabled correlations between epigenetic modifications and a 
number of phenotypes to be established. However, addressing narrower questions of 
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causation and whether the presence of a mark at a specific locus is causing a specific 
phenotype requires more specific, targeted approaches. 
 
As a result, over the last few years much work has been put into the creation of specific 
chromatin editors as a more targeted and potentially informative approach relative to the 
global epigenetic changes induced by chemical approaches (Cole, 2008). Similar to the 
problems faced with the construction of synthetic transcription factors, one of the key 
issues has been identifying and testing appropriate effector domains, in this case for 
inducing targeted epigenetic modifications. 
 
One of the earliest chromatin editors employed as a DNA binding fusion protein was 
originally tested and characterised a transcriptional repressor protein (Deuschle et al., 
1995). The KRAB domain, was subsequently shown to mediate its effects through 
heterochromatin formation, through the recruitment of proteins capable of laying a 
trimethyl mark on histone 3, lysine 9 (H3K9me3) (Groner et al., 2010; Ryan et al., 1999; 
Schultz et al., 2002; Sripathy et al., 2006) (Figure 1-4A). As such the KRAB domain also 
possesses uses beyond direct transcriptional repression, for example a recent paper 
highlighted the use of KRAB to repress distal enhancers (Thakore et al., 2015). Thakore and 
colleagues showed that targeting of dCas9-KRAB to the HS2 distal enhancer down-
regulated the expression of the global genes HBE1 and HBG1/2, after quantifying relative 
expression with qRT-PCR. Alternative repressors have also been developed, in part due to 
the fact the KRAB domain can induce repression when targeted to distal or proximal 
elements associated with a gene (Gao et al., 2014; Gilbert et al., 2014, 2013; Kearns et al., 
2015). LSD1 has been characterised to induce demethylation of mono and di-methylated 
lysine 4 and 9 on the H3 histone (Metzger et al., 2005; Shi et al., 2004). By targeting LSD1 
using a TALE and dCas9 fusions, Kearns and colleagues were able to demonstrate robust 
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repression of TBX3 when targeted to the distal enhancer Enh1 but not when targeting to 
the proximal promoter (Kearns et al., 2015). 
 
Through the adaptation of the histone acetyltransferase p300 (Ogryzko et al., 1996), 
researches have also demonstrated the capacity to induce an open chromatin state at 
targeted loci, with dCas9 based recruitment of the p300 catalytic core (Hilton et al., 2015) 
(Figure 1-4B). They also went on to show that they could induce transactivation through 
the targeting of a distal enhancers for MYOD and OCT4 as well as the β-globin locus. 
 
 
Figure 1-4 - Synthetic chromatin editors 
A) Diagrammatic representation of the action of dCas9-KRAB to enable laying of the formation of 
heterochromatin, leading to gene repression. This is achieved through the recruitment of secondary 
proteins KAP1 and SETDB1, which lay the histone 3 lysine 9 trimethyl mark on proximal 
nucleosomes. B) Diagrammatic representation of the action of dCas9-p300. As a histone acetyl-
transferase, p300 directly acetylates proximal histones, leading to increased turnover of histones 


















The previously described chromatin editors modified the histones that DNA associates 
with. However, researchers have also tethered domains onto dCas9, that directly modify 
the methylation of DNA, associated with transposon silencing (Goll and Bestor, 2005) and 
repression of promoters (Suzuki et al., 2007). Tet1 DNA demethylase has been tethered to 
dCas9 and targeted to the FMR1 gene to demethylate the CGG repeats found in the 5’UTR, 
responsible for Fragile X Syndrome. Liu and colleagues showed that they could observe 
sustained DNA demethylation and increased gene expression over a two week period, with 
rescue of the hyperactive electrophysiological phenotype observed for edited patient 
derived neurons (Liu et al., 2018). In contrast, by fusing the DNA methyltransferase Dnmt3a 
to dCas9 and targeting it to a promoter driving GFP expression, they observed both an 
increase in methylation of the promoter region, alongside a corresponding increase in GFP 
negative cells (Liu et al., 2016). 
 
1.8 Cas12a 
It is important to remember when considering CRISPR approaches that Cas9 represents 
only one of several functional gRNA driven endonucleases. In fact with the discovery and 
further characterisation of Cas12a (formerly Cpf1) (Zetsche et al., 2015a), it appears that 
alternative CRISPR systems may offer unique advantages that can enable them to 
complement and for some applications supersede the existing Cas9 derived toolkits. 
 
Similarly to Cas9, Cas12a is a homing endonuclease, relying upon a crRNA sequence to 
confer target specificity and like Cas9, Cas12a is a class 2 CRISPR system, with interference 
activity being achieved by a single multi domain protein (Figure 1-5A). However, initial 
characterisation of Cas12a by Zetsche and collegues showed Cas12a possessed a number of 
unique properties (Zetsche et al., 2015b). They observed that Cas12a does not to require a 
tracrRNA for targeting. They also showed that in contrast to Cas9 DNA cleavage by Cas12a 
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produces a staggered break with a 5’ overhang and is initiated by a RuvC-like domain 
(Figure 1-5A). Unlike for Cas9, which requires two independent amino acid substitutions to 
abolish DNA cleavage, a single amino acid substitution in the RuvC domain (E993A) can 
inhibit cleavage for both strands. For the 16 Cas12a variants they screened, they were able 
to identify clear PAM sequences for 8 and went on the show cleavage in mammalian cells 
for two of these variants: Acidaminococcus sp (AsCas12a) and Lachnospiraceae bacterium 
(LbCas12a). These were originally characterised to have PAM sequences of TTTN, however 
subsequent publications have refined this, demonstrating that the two variants optimally 
target a TTTV PAM sequence (Kim et al., 2017).   
 
After initial characterisation by Zetsche and collegues, most subsequent application of 
Cas12a have focussed on the As and Lb variants, as the original work suggested only these 
variants could successfully cleave DNA in mammalian cells (Zetsche et al., 2015a). AsCas12a 
has been applied for editing humanised liver cells in mice (Tsukamoto et al., 2018) and 
mice neurons (Zetsche et al., 2017) through in vivo delivery with adeno-associated virus 
(AAV). LbCas12a has been applied for the generation of an APOE knockout rat, serving as a 
model for atherosclerosis (Lee et al., 2019) as well as for the correction of dystrophin 
mutations responsible for muscular dystrophy in both human cardiomyocytes and mice 
(Zhang et al., 2017). Of interest, despite initial analysis by Zetsche et al. showing activity in 
human cells for only the As and Lb variants, work by Tu et al. showed that the Francisella 
tularensis subsp. novicida U112 derived Cas12a (FnCas12a) also showed robust cleavage 
activity when targeting three different genomic loci across three different genes (Tu et al., 
2017). This was also extended to Moraxella bovoculi 237 derived Cas12a (MbCas12a), with 
work by Tóth et al. which showed that non-homologous recombination and homology 
directed recombination could be achieved for the Fn and Mb variants alongside the As and 
Lb (Tóth et al., 2018).  
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A number of studies have been conducted to enhance the capabilities of the wild-type 
variants of Cas12a and to improve cleavage activity and targeting capabilities for Cas12a. 
Park et al. showed that by extending the 5’ of the crRNAs, they were able to observe 
increased gene editing when targeting reporter constructs in HEK293 cells (Park et al., 
2018). Gao et al. were subsequently able to generate two variants of AsCas12a (‘RR’ and 
‘RVR’) that could target TYCV and TATV PAM sequences, as opposed to the TTTV PAM 
sequence for the original AsCas12a (Gao et al., 2017). Finally, drug inducible cleavage has 
been enabled for AsCas12a through the insertion of the oestrogen receptor domain into a 
flexible loop, with cleavage only being observed when tamoxifen was present (Dominguez-
Monedero and Davies, 2018).  
 
A number of tools have now been developed to facilitate crRNA selection and increase the 
likelihood of successful genome editing. These include work by Park and colleagues who 
developed software to enable rapid design of crRNAs for genome-wide screening 
experiments, using As and Lb variants (Park et al., 2018). Kim et al. went on to utilise a 
large dataset of AsCas12a cleavage activity and chromatin accessibility data to train a deep-










Figure 1-5 - Comparison of Cas9 and Cas12a 
A) Diagrammatic representation of some of the key differences between Cas9 and Cas12a. Cas9 
recognises a G rich PAM sequence to the 3’ of the protospacer sequence and melts the DNA to 
enable hybridisation by the spacer sequence of the crRNA (fused to a tracrRNA) before inducing a 
blunt double-strand break. Cas12a recognises a T rich PAM sequence to the 5’ of the protospacer 
sequence and melts the DNA to enable hybridisation of the spacer sequence of the crRNA, before 
inducing a staggered 4/5bp double strand break. B) Cas12a unlike Cas9 possesses RNase activity that 
enables it to process it’s own crRNA array, enabling a single crRNA array transcript expressed 











































1.9 crRNA arrays 
Initial work by Zetsche et al. also showed that crRNA arrays, composed of multiple tandem 
targeting crRNAs, could be processed when only Cas12a and the crRNA array were 
expressed, without further Cas proteins or tracrRNA (Zetsche et al., 2015a) (Figure 1-5B). 
Subsequent work by Fonfara et al. went on to show that FnCas12a possesses RNase activity 
and is sufficient to process crRNA array in vitro (Fonfara et al., 2016). This ability to process 
a crRNA array provides a greatly simplified strategy for the delivery of multiple gRNAs, 
when compared to Cas9. For Cas9 systems gRNAs must either be expressed from multiple 
transcriptional units or using more complicated strategies relying upon co-delivery of an 
endoribonuclease (Nissim et al., 2014), or the flanking of the gRNAs with 
ribozymes/tRNA (Nissim et al., 2014)(Zhang et al., 2017) genes to enable appropriate 
processing. 
 
A number of groups have showcased the strength of using arrays for targeting, with 
applications for multiplexed gene editing (Zetsche et al., 2017) as well as synergistic and 
multiplexed transactivation observed in human cells (Tak et al., 2017)(Zhang et al., 2018) 
alongside multiplexed repression (Campa et al., 2019). 
 
1.10 Cas12a repression 
Alongside work with wild-type Cas12a, researchers have also explored the adaptation of 
CRISPR/Cas12a for repression of gene expression. Utilising the E993A mutation originally 
characterised by Zetsche et al. to abolish cleavage activity, Zhang et al. showed that gene 
repression could be achieved by employing dAsCas12a in E. coli (Zhang et al., 2017), similar 
to what had previously been shown in E. coli using dCas9 (Gilbert et al., 2013). However, 
similarly to observations for dCas9, minimal repression was observed when dAsCas12a was 
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targeted, with a 2-fold repression being achieved only when three crRNAs were 
simultaneously targeted to a CMV promoter controlling the expression of GFP (Liu et al., 
2017). The same publication showed that by tethering the KRAB domain to the C-terminus 
of dAsCas12a, higher than two-fold repression could be achieved with single crRNAs, which 
became further pronounced when multiple unique crRNAs were co-delivered to the 
HEK293T cells.  
 
1.11 Cas12a synthetic transcription factors 
Researchers also demonstrated the capacity of dCas12a scaffolds to enable recruitment of 
transactivation domains to genomic loci to serve as synthetic transcription factors. Initial 
work by Tak and colleagues demonstrated that by tethering either the p65 or VPR domain 
to dLbCas12a, they could observe significant transactivation for targeted genes in HEK293 
cells, however this transactivation was significantly higher when the VPR domain was 
employed (Tak et al., 2017). In the same study they also demonstrated the use of the 
chemically inducible dimerisation domains DmrA and DmrC (Rivera et al., 2012), which 
recruited the two individual effector domains to dLbCas12a when the A/C heterodimeriser 
compound was present. Finally they also went on to employ a series of 3-crRNA arrays. 
When comparing the transactivation observed for an array possessing three crRNAs 
targeting dLbCas12a-VPR to a single promoter, compared to the transactivation enabled by 
each individual crRNA, they were able to see not only higher, but synergistic 
transactivations for two of the three genes tested. This meant that the crRNA arrays were 
able to induce a greater transactivation than the predicted additive effect from combining 
each of the single crRNAs. Subsequent work has confirmed the efficacy of dLbCas12a-VPR. 
Zhang and colleagues not only showed that dLbCas12a-VPR was able to more robustly 
transactivate compared to dLbCas12a across a number of targets (Zhang et al., 2018).  
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The capacity for dAscCas12a-VPR to also induce robust transactivation in mammalian cells 
was demonstrated by Liu and colleagues, who also observed increased activity when a pool 
of three crRNAs were targeted compared to the individual crRNA (Liu et al., 2017). They 
went on to show that through the incorporation of either a tetracycline or theophylline 
aptamer in the 3’ end of the crRNA, they were able to generate druggable crRNA, where 
the presence of the respective ligand would lead to a conformational change that enabled 
binding of the crRNA to the target sequence. They showed that increasing the 
concentration of tetracycline or theophylline led to improved transactivation across up to 
100 μM and 1000 μM respectively. Finally they also showed that they could employ a G-
protein coupled receptor (GPCR) for inducible co-localisation of the TEVp and TCS domain 
upon ligand binding to the receptor, enabling cleavage and release of dAsCas12a-VPR. They 
again observed increased transactivation, when employing two different GPCRs, as the 
ligand concentration was increased. 
 
Finally work by Zhang et al., explored the application of the p300 histone acetyltransferase 
for transactivation (Zhang et al., 2018). They initially screened dAsCas12a and dLbCas12a 
with a C-terminal fusion of the p300 core domain, targeting with four crRNAs to either the 
MYOD or IL1RN promoter. However they only observed significant transactivation for 
dLbCas12a-p300. They proceeded to show that, similarly to dCas9-p300, dLbCas12a-p300 
could transactivate downstream genes when targeted to a distal enhancer. They also 
adapted dLbCas12a to the SunTag system previously described. This system uses a tandem 
array of peptides, that can be bound by short antibody fragments, fused to the CRISPR 
scaffold to enable recruitment of effectors bound to the antibody fragments. They showed 
that by fusing the tandem array of peptides to dLbCas12a they were able to recruit 
transactivation domains and induce robust transactivation for three different target genes, 
when providing an individual targeting crRNA. 
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1.12 Scope of this thesis 
Whilst techniques have been developed to enable specific transactivation of targeted 
genes, several limitations have remained, that provide challenges when applying synthetic 
transcription factors as tools, as well as limiting potential for therapeutic applications. Here 
we focus on Cas12a and its adaptation as a synthetic transcription factor. Studies published 
during the course of this work successfully showed that Cas12a derived synthetic 
transcription factors could be generated for As and Lb Cas12a. We initially show in Chapter 
3 that for the As variant transactivation can be achieved through N-terminal as well as C-
terminal transactivation. In Chapter 4 we demonstrate that the FnCas12a variant 
(possessing a shorter PAM sequence) can be adapted as a synthetic transcription factor and 
perform a comparison of the As, Fn and Lb synthetic transcription factors, exploring activity 
and orthogonality. We confirm activity of the dFnCas12a-VPR synthetic transcription factor 
when independently targeting three endogenous genes in mammalian cells, also observing 
that increased transactivation is possible when multiple significantly activating crRNAs 
target a single promoter. In Chapter 5 we demonstrate that short arrays can enable 
transactivation of target genes by dFnCas12a-VPR and in some cases synergy (greater than 
the additive transactivation of the individual crRNAs) can be observed. We explore the 
crRNA arrays, testing up to 9-crRNA arrays expressed from a pol3 promoter and observe 
that transactivation is achieved, however there is reduced activity for the crRNAs are 
positioned closer to the 3’ of the array. Finally, we go on to show evidence that 





Chapter 2 Materials and methods 
 
2.1 Molecular Biology techniques 
2.1.1 Oligo annealing 
Oligonucleotides were annealed by adding 42 μl of ddH₂O with 5 μl of NEB buffer 3.1 (NEB 
cat # B7203S), 1.5 ul of 100 μM of the template strand oligonucleotide and 1.5 ul of 100 
μM of the non-template strand oligonucleotide to a sterile PCR tube. The reaction was 
incubated in a thermal cycler with the following protocol. Cycle 1 set at 98ºC for 10 
minutes, then 60 subsequent cycles, where the temperature was lowered by 1ºC for 60 
cycles. The final step was set at 16ºC held indefinitely.  
 
2.1.2 PNK + Ligase treatment 
As crRNA arrays were constructed using ordered oligos, phosphorylation was necessary for 
successful ligation. For PNK treatment and ligation of inserts to a backbone vector, the 
following reagents were combined in a PCR tube on ice; 2 μl T4 DNA Ligase buffer (NEB cat 
#B0202S), 1 μl PNK (NEB cat #M0201S), 1 μl T4 DNA Ligase (NEB cat #M0202), vector DNA, 
insert DNA and ddH₂O to 20 μl. For generating single crRNA vectors, 50 ng of of Bpi1 
digested pU6 vector backbone was added with 1 μl of annealed oligos for the crRNA of 
interest. The reaction is incubated in a thermal cycler at 37ºC for 30 minutes, then held at 
4ºC indefinitely. 
 
2.1.3 Bacterial plates and liquid media 
LB media was prepared by adding the following components; 5 g of tryptone (BD diagnostic cat# 
211705), 2.5 g of yeast extract (BD diagnostic cat # 212710), 5 g of sodium chloride, 7.5 g of agar 
(only for plates). These were dissolved in 500 ml of ddH₂O and autoclaved.  
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LB media requiring antibiotics was made by adding ampicillin from stock solution (100 mg/ml) to a 
final concentration of 100 µg/ml or adding kanamycin from stock solution (50 mg/ml) to a final 
concentration of 50 µg/ml. 
 
2.1.4 Chemically competent cell preparation 
SOB media was made by mixing the following components; 20 g of tryptone, 5 g of yeast 
extract, 0.58 g of sodium chloride and 0.19 g of potassium chloride. These were dissolved in 
500ml of sterile ddH₂O then autoclaved 
 
The CCMB buffer was prepared by dissolving the following components; 5.9 g of calcium 
chloride dihydrate (Sigma cat # 223506-500G), 2 g of manganese (II) chloride tetrahydrate 
(Sigma cat # 221279-100G), 1 g of magnesium chloride hexahydrate (Sigma cat # M9272-
100G), 500 ml of 5M potassium acetate (Sigma cat # 95843-100ML-F) and 50 ml of glycerol. 
All these components were dissolved in 500 ml of ddH₂O then filter sterilised (Sarstedt cat# 
83.1823) 
 
The E. coli Mach 1 (F– φ80lacZΔM15 ΔlacX74 hsdR(rK–, mK+) ΔrecA1398 endA1 tonA) 
competent cells was purchased from Thermo fisher (cat # C862003). Cells were streaked 
out on LB plates without selection and grown overnight in a 37℃ incubator. An overnight 
liquid culture of these strain was prepared by inoculating 5 ml of LB (without selection) 
with a colony of the E. coli cells streaked on the LB plate. This was grown overnight in a 
shaker (Infors HT Multitron Pro) set at 200 rpm at 37℃. The overnight cultures were used 
to inoculate 500 ml of SOB media and grown in a shaking incubator set at 200 rpm in 37℃ 
till an OD of 0.4 (approximately 2 hours). On ice in sterile conditions, the cells are pelleted 
in centrifuge tubes at 3,000 rpm for 2 minutes in 4℃. The supernatant was discarded. The 
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pellet was resuspended in 100 ml of CCMB then pelleted at 3,000 rpm for 2 minutes at 4℃ 
and the supernatant was subsequently discarded. The pellet was resuspended in 50 ml of 
CCMB then pelleted at 3,000 rpm for 2 minutes at 4℃ and the supernatant was 
subsequently discarded. The pellet was resuspended in 20 ml of CCMB then incubated on 
ice for 30 minutes to 2 hours. The cells were then aliquoted in 50 µl aliquots, flash frozen 
on dry ice then stored at -80℃. 
 
2.1.5 E. coli transformation by heat shock 
Plasmid DNA were transformed into chemically competent E. coli Mach1 cells by heat 
shock. Competent cells previously prepared (in 50 µl aliquots) were thawed. In sterile 
conditions, DNA was added to the reaction and kept on ice for 15 minutes. The reaction 
was transferred to a water bath set at 42℃ for 45 seconds then incubated on ice for 5 
minutes. In sterile conditions, 500 µl of SOC was added to the transformation reaction and 
incubated at 37℃ for 1 hour. The cells are pelleted by centrifugation at 13,000 g for 1 
minute and 400 µl of the supernatant was removed. The remaining supernatant was used 
to resuspend the pellet. The cell suspension was plated on LB with selection (antibiotics) 
and evenly spread using a disposable plastic spreader. These plates were incubated at 37℃ 
overnight. 
 
2.1.6 Plasmid extraction from bacterial cultures 
5 ml of LB with the appropriate antibiotic selection (100 µg/ml for ampicillin or 50 µg/ml 
for kanamycin) was aliquoted into 15 ml centrifuge tubes (Sarstedt cat # 62.554.001) and 
inoculated with bacterial colonies containing the desired plasmids. These cultures were 
grown overnight in a 37℃ shaker (Infors HT Multitron Pro) set at 200 rpm. Plasmids were 
extracted using the E.Z.N.A. Plasmid mini kit I (Q-spin) (Omega Biotek cat #D6942-01) 
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according to the manufacturer’s instructions. Plasmids were eluted in 50 µl ddH₂O. The 
concentration was measured using a nanodrop. 
 
2.1.7 PCR amplification 
PCR amplification reactions to construct plasmids were performed using the Q5 DNA 
polymerase.  The PCR reaction was prepared by adding 1x Q5 reaction buffer (5 µl), 0.2 mM 
dNTPs (1 µl), 0.001 U of Q5 high fidelity polymerase (0.5 µl), 0.5 µM of the forward primer, 
0.5 µM of the reverse primer, 1 µl of the template DNA for a final volume of 50 µl. The PCR 
was incubated in a thermocycler with the following program: 98°C for 30 seconds; 35 
cycles of 98°C for 10 seconds, 55°C for 30 seconds and 72°C for 30 seconds; 72°C for 
2 minutes; hold at 4°C.  
 
2.1.8 PCR purification 
PCR products were purified using the QIAquick PCR purification kit (Qiagen cat #28104) 
according to the manufacturer’s protocol. 
 
2.1.9 Restriction digestion 
Digestion of plasmids and PCR products were prepared by mixing 1 µl of plasmid DNA with 
1 µl of restrictions enzyme (NEB) and 1x appropriate buffer for the enzyme (NEB) (5 µl) to a 
final volume of 50 µl. The reaction was incubated at 37°C for 1-2 hours and size verified by 
agarose gel electrophoresis 
 
2.1.10 Agarose gel electrophoresis 
PCR products and digestion reactions were verified by gel electrophoresis. 1% or 2% 
agarose gel was prepared, depending on the expected size of the band. This was prepared 
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by weighing the appropriate amount of agarose and measuring the corresponding volume 
of TAE buffer according to the desired gel percentage. The agarose-TAE mixture was 
microwaved until the agarose is completely dissolved. The mixture was allowed to cool at 
55°C. SYBR safe DNA gel stain (Thermo cat #S33102) was added, mixed thoroughly and 
poured on a casting tray and allowed to set. 
 
PCR products and digests were mixed with 6x gel loading dye (NEB cat #B7024S) and 
loaded onto the gel. The agarose gel was run at 125V for 15 minutes in 1xTAE buffer then 
imaged using a gel documentation system (BioRad Gel Dox XR+) 
 
2.1.11 Gel extraction and purification 
Digested plasmids or DNA fragments ran on a gel were separated by size and the desired 
band was excised using a scalpel and purified using the QIAquick Gel Extraction Kit (Qiagen 
cat #28704) according to the manufacturer’s instructions 
 
2.1.12 Sanger sequencing  
Purified plasmids were sent for sequencing, along with the appropriate primers, to the 
MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) DNA sequencing and services 
at the University of Dundee. 
 
2.1.13 Gibson assembly 
Gibson assembly was carried out using the NEB HiFi Gibson assembly master mix (NEB cat # 
E2621S). 10 µl of the Gibson assembly master mix reaction was prepared instead and 
plasmid:insert DNA was added at a 1:1 ratio. The reaction was incubated at 50℃in a 
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thermocycler for 1 hour and subsequently kept on ice for 5 minutes. The reaction was then 
transformed into E. coli competent cells according to the method in section 2.1.5. 	
 
2.1.14 Semi-dry Western Blot 
The following transfer buffer was first prepared: 3.03 g/L Tris base, 14.4 g/L glycine, 20 % 
methanol, Up to 1L dH20. Previously extracted protein samples (resuspended in SDS 
reducing buffer) were boiled for 5 minutes at 95, before being run in transfer buffer on a 4-
15% Mini-PROTEAN® TGX™ Precast Gels alongside NEB Broad-range protein standard. 
Transfer was performed using a BioRad Mini Trans-Blot® Electrophoretic Transfer Cell, with 
a PVDF membrane (BIORAD), pre-activated by soaking in Methanol for 15 minutes. After 
transfer the blots were blocked overnight in 5% milk powder in PBS-T (PBS with 0.1% 
TRITON-X). The blots were then exposed to the primary antibodies (1:5000 unless 
otherwise stated) for 1hour, before washing the blot with 5% milk powder in PBS-T and 
applying the appropriate HRP secondary antibody (1:5000 unless otherwise stated). The 
western blot was subsequently washed with PBS-T and the blot was imaged using the LI-
COR C-DiGit Blot Scanner. 
 
2.2 Mammalian cell culture techniques 
 
2.2.1 HEK293FT media preparation 
Media for growing HEK293FT cells was prepared by supplementing Dulbecco’s modified 
Eagle’s medium (DMEM) (Thermo Fisher cat #31966021) with 10% Fetal bovine serum 
(FBS) (Thermo Fisher cat #16000036), 4 mM L-glutamine (cat #) and 1% penicillin 
streptomycin (Thermo Fisher cat #15140122) 
 
 30 
2.2.2 Automated cell counting 
In a T75 flask, add 2 ml of TrypLE Express Enzyme (Thermo Fisher cat #12605010) to release 
the cells from the bottom of the flask. 10 µl of Trypan blue solution (Thermo Fisher cat 
#15250061) was added to 10 µl of cells. 10 µl of the mixture was pipetted into the 
Countess Cell Counting Chamber Slides (Thermo Fisher cat #C10228). The slide was 
inserted into the Countess II Automated Cell Counter (Invitrogen cat #15397802). The cell 
counting process was started and relevant statistics were recorded. 
 
2.2.3 Freezing down cells (-80℃) 
The freezing media was prepared by mixing 50% HEK293FT media, 40% Fetal calf serum 
(FCS) and 10% DMSO. Split cells were resuspended in freezing media and transferred to 
cryotubes. They are kept on ice for 30 minutes then wrapped in tissue before transferring 
them to a -80℃ freezer for long term storage.  
 
2.2.4 Mammalian cell transfection (lipofection) 
Cells were seeded 1 day prior to transfection in a 24 well plate then on the day of 
transfection, a working solution of diluted Lipofectamine was prepared (Thermo Fisher cat 
#11668027) with the relevant amount of OptiMEM medium (Thermo Fisher cat #31985-
047) (25 µl of OptiMEM per 1 µl of Lipofectamine). 25 µl of OptiMEM was aliquoted into 
eppendorfs, corresponding to each well to be transfected. DNA to be transfected was 
added to the eppendorf tubes containing OptiMEM. 25 µl of diluted Lipofectamine working 
solution was added to each eppendorf tube resulting in a total mixture volume of 50 µl. 
The solution was then gently mixed and incubated at room temperature (20-22℃) for 5 
minutes. After incubation, the OptiMEM-DNA-lipofectamine mix was transferred to the 
cells on the 24 well plate. 
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2.3 Screening techniques 
 
2.3.1 Luciferase assay 
This Luciferase assay utilises the expression of two luciferase genes (Firerfly Luciferase and 
Renilla Luciferase). Upstream of the minimal promoter driving Firefly Luciferase are 
multiple binding sites for crRNA or gRNAs to test the activity of their corresponding 
synthetic transcription factors (dCas12a-VPR for crRNAs and dCas9-VPR for gRNA). The 
detected luminescence level of Firefly Luciferase was compared to a Renilla luciferase 
constitutively expressed from a separate plasmid to determine any up regulation in gene 
expression by the synthetic transcription factor.  
 
Plasmids constructed to contain crRNAs targeting the multiple binding sites upstream of 
the minimal promoter driving Firefly Luciferase were transfected along with the plasmid 
containing the dCas12a-VPR synthetic transcription factor. As a positive control, a plasmid 
containing gRNA targeting the multiple binding sites upstream of the minimal promoter 
driving Firefly Luciferase was transfected along with the plasmid containing the dCas9-VPR. 
 
These plasmids (gRNA and dCas9-VPR plasmid pair or crRNA and dCas12a-VPR plasmid 
pair) were transfected along with a Firefly luciferase reporter and a Renilla luciferase 
internal control plasmid previously constructed at the Rosser lab. After 48 hours post-
transfection, the HEK293FT cells were lysed with Passive Lysis buffer. The Firefly and Renilla 
luciferase induced luminescences for each sample were measured using the Dual Luciferase 




2.3.2 RNA extraction, Reverse transcription (cDNA synthesis) and Quantitative RT-
PCR 
Three days post transfection, cells were harvested. The addition of TrypLE Express Enzyme 
(Thermo Fisher cat #12605010) released the cells from the bottom of the well, pelleted by 
centrifugation then resuspended in RNA lysis buffer. The RNA was then extracted using the 
E.Z.N.A Total RNA Kit 1 (Omega Biotek cat #R6834-01) according to the manufacturer’s 
instructions. The concentration and RNA quality was assessed using the nanodrop. 1 µg of 
RNA was mixed with 1μl of 50μM oligo d(T)20 (IDT), 1μl of 10mM dNTP mix (Promega cat 
#U1240) and dd H20 up to a final volume of 13μl in a PCR tube and incubated at 65℃ for 5 
minutes then on ice for 1 minute. The following components were added to each sample; 
4μl of SuperScript IV Reverse Transcriptase buffer, 1μl of 0.1 M DTT, 1ul of dH20, 0.5μl of 
RiboLock RNase Inhibitor (Thermo Scientific cat #EO0381) and 0.5μl of SuperScript IV 
Reverse Transcriptase (Thermo Fisher cat #18090050). The reactions were incubated at 
52ºC for 10 minutes followed by 80ºC for 10 minutes and holding at 4℃. A qPCR reaction 
plate was set up with Power SYBR Green qPCR mix (Thermo Fisher cat #4367659), diluted 
cDNA and primers and ran on the StepOnePlus real-time PCR machine (Thermo Fisher cat 
#4376600). The results were analysed on the StepOnePlus PCR machine software.  
 
2.3.3 ChIP qPCR 
ES cells (provided by Elin Ennervald) were treated with typsin before being spun down and 
washed with PBS The cells were subsequently resuspended in 18ml PBS and 2ml 10x cross 
linking buffer. After 10 minutes, rotating at room temperature, the cross-linking reaction 
was quenched with 2.2ml of Glycine (final concentraltion 125mM. From each plate ~2.5e7 
cells were used for H3K27ac ChIP-enrichment.  
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Chromatin was sheared to a median fragment size of 250 bp using a Bioruptor XL 
(Diagenode). H3K27ac enrichment was performed by incubation with 5 μg of Abcam 
(ab4729) and 200 μl of sheep anti-rabbit IgG magnetic beads (Life Technologies 11203D) 
for 16 hrs at 4°. Cross-links were reversed via overnight incubation at 65°C with sodium 
dodecyl sulfate, and DNA was purified using MinElute DNA purification columns (Qiagen). 
10ng of DNA was used for subsequent qPCR analysis. The ratio of the enriched to 1% INPUT 
was calculated for positive and negative control conditions to ascertain the fold enrichment 
at the positive control loci. 
 
2.3.4 Screening for synergy 
When screening for synergy, we defined synergy as the combined (pooled or array) 
experimentally derived distribution being significantly higher than the hypothetical 
distribution expected from adding the distributions of the composite crRNAs normalised to 
the negative control. Using this approach we are able to infer the mean of the hypothetical 
distribution by adding the geometric mean of the fold changes (calculated by taking 2^-CT) 
and taking the log base 2 of this value to generate the CT distribution for the hypothetical 
additive condition. 
 
Mean (A+B) = log2(Geometric mean(Fold change A) + Geometric mean (Fold change B))  
 
We calculated the variance of the mean using standard error propagation; var (f(x,y)) / 
(f(x,y))2 = (partial derivative f(x,y) / partial derivative x) 2 x2 + (partial derivative  f(x,y)/ 
partial derivative x) 2. 
 
By taking the square root of the variance of the hypothetical condition, we can calculate 
the standard deviation. With the respective means and standard deviations for the 
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combined (pool/array) conditions and the hypothetical additive conditions, a Welch’s t test 
can be performed to ascertain the level of significance of separation observed for the two 
distributions. 
 
2.3.5 Statistical tests 
All statistical tests were performed using Prism 8 software. Where levels of significance are 
displayed on graphs using stars, the stars represent the P values as follows; * = P < 0.05, ** 
= P < 0.01, *** = P < 0.001. 
 
2.4 Primer list 
Table 2.1 - Table of primers used in this study 
Primer name Primer sequence 
As-OuterF GGA GAA GGT GCA GCG CAG CC 
As-Mut1F GAC ACC TAT CAT CGG CAT CGC GCG GGG CGA GA 
As-Mut1R CAG GTT TCT CTC GCC CCG CGC GAT GCC GAT G 
OuterR TAG GGA TAA GCG TAA TCT GGA ACA TCG TAT GG 
Fn OuterF TAG GGA GAC CCA AGC TGG CTA GC 
Fn Mut1R TGC CGC TCT CCT CGC GCA ATG CTC AGG ATG TGC 
Fn Mut1 F ACG ATG TGC ACA TCC TGA GCA TTG CGC GAG GAG AGC 
Lb Outer F AGT ATG ACG ATA TCC ACC TGA AGA AGA AGG C 
Lb Mut1R CAG ATT GCG CTC GCC CCT CGC GAT GCC GAT 







As luc g F CACCGTAATTTCTACTCTTGTAGATCAGGCTAGCCATGCTTCGCT 
As luc g R 
AAA CAG CGA AGC ATG GCT AGC CTG ATC TAC AAG AGT 
AGA AAT TAC 
Fn luc g R 
CAC CGT AAT TTC TAC TAA GTG TAG ATC AGG CTA GCC ATG 
CTT CGC T 
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Fn luc g1 R 
AAA CAG CGA AGC ATG GCT AGC CTG ATC TAC ACT TAG TAG 
AAA TTA C 
Lb luc g1 F 
CAC CGT AAT TTC TAC TGT TGT AGA TCA GGC TAG CCA TGC 
TTC GCT 
Lb luc g1 R 
AAA CAG CGA AGC ATG GCT AGC CTG ATC TAC AAC AGT 
AGA AAT TAC 
As g1 F 
CACCGGTAATTTCTACTCTTGTAGATCAAGCTAGCCATGCTTCGC
T 
As g1 R 
AAACAGCGAAGCATGGCTAGCTTGATCTACAAGAGTAGAAATT
ACC 
As g2 F 
CACCGGTAATTTCTACTCTTGTAGATCAGGCTAGTCATGCTTCGC
T 
As g2 R 
AAACAGCGAAGCATGACTAGCCTGATCTACAAGAGTAGAAATT
ACC 
As g3 F 
CACCGGTAATTTCTACTCTTGTAGATCAGGCTAGCGGGGGGCTA
TA 
As g3 R 
AAACTATAGCCCCCCGCTAGCCTGATCTACAAGAGTAGAAATTA
CC 
Lb g1 F 
CACCGGTAATTTCTACTGTTGTAGATCAAGCTAGCCATGCTTCGC
T 
Lb g1 R 
AAACAGCGAAGCATGGCTAGCTTGATCTACAACAGTAGAAATTA
CC 
Lb g2 F 
CACCGGTAATTTCTACTGTTGTAGATCAGGCTAGTCATGCTTCGC
T 
Lb g2 R 
AAACAGCGAAGCATGACTAGCCTGATCTACAACAGTAGAAATTA
CC 
Lb g3 F 
CACCGGTAATTTCTACTGTTGTAGATCAGGCTAGCGGGGGGCTA
TA 
Lb g3 R 
AAACTATAGCCCCCCGCTAGCCTGATCTACAACAGTAGAAATTA
CC 










N term As F 
ATGACACAGTTCGAGGGCTTTACCAACCTGTATCAGGTGAGCAA
GACACT 
N term As R TCGCTGGTTTTCTGCTTGAAGGCCTCGCTCAGCTCC 
As PmlI F GCG ACA AGT TCT TTT TCC AC 
As Site 1 PmlI R CAC GTC GTA GTG CAG AAA GT 
As Site 1 BamHI F AAA ACC GGC GAC TTC ATC CT 
As BamHI R CTG GAA CAT CGT ATG GGT AG 
As Site 2 BamHI F GAT GGC TCC AAC ATC CTG CC 
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As Site 2 PmlI R CCT GAA CAC GAT GCC CTT CT 
VP64 Site1 5AA F 
ACT TTC TGC ACT ACG ACG TGG GTG GCT CTG GAG GTG ACG 
CAT TGG ACG ATT TTG 
VP64 Site1 5AA R 
AGG ATG AAG TCG CCG GTT TTT CCT CCA CTA CCG CCC AGC 
ATG TCC AGG TCG 
VP64 Site2 5AA F 
AGA AGG GCA TCG TGT TCA GGG GTG GCT CTG GAG GTG 
ACG CAT TGG ACG ATT TTG 
VP64 Site2 5AA R 
GGC AGG ATG TTG GAG CCA TCT CCT CCA CTA CCG CCC AGC 
ATG TCC AGG TCG 
Outer Alaz As F CACGAGGATATCAACCTGCAGGAGATCATC 
Inner Alaz As R CTCTGTGGGCTCGAAGCTCAGG 
VP64 Alaz  As F 
TGAGCTTCGAGCCCACAGAGGACGCATTGGACGATTTTGATCTG
GATATGCT 
VP64 Alaz As R 
TCAAAGCCCTCGCTGGTTTTCAGCATGTCCAGGTCGAAATCATC
AAG 
Inner Alaz  As F AAAACCAGCGAGGGCTTTGATAAGATGTACTATGAC 
Outer Alaz As R TAGTTCAGTGTGATAGGCACGTGGAAAAAGAACTTG 
Alt PAM As Luc F 
CACCGGTAATTTCTACTCTTGTAGATAGGCTAGCCATGCTTCGCT
A 
Alt PAM As Luc R 
AAACTAGCGAAGCATGGCTAGCCTATCTACAAGAGTAGAAATTA
CC 
Alt PAM Fn Luc F 
CACCGGTAATTTCTACTGTTGTAGATAGGCTAGCCATGCTTCGCT
A 
Alt PAM Fn Luc R 
AAACTAGCGAAGCATGGCTAGCCTATCTACAACAGTAGAAATTA
CC 
Alt PAM Lb Luc F 
CACCGAATTTCTACTAAGTGTAGATAGGCTAGCCATGCTTCGCT
A 
Alt PAM Lb Luc R aaacTAGCGAAGCATGGCTAGCCTATCTACACTTAGTAGAAATTC 
First AR MST F CACCGAATTTCTACTAAGTGTAGATAGAGTC 
First AR MST R CTCATCCAGACTCTATCTACACTTAGTAGAAATTC 
AR MST 2 F TGGATGAGAAATGCAATTTCTACTAAGTGTAGATTACCCT 
AR MST 2 R CAGAGAAGAGGGTAATCTACACTTAGTAGAAATTGCATTT 
AR MST 3 F CTTCTCTGCCTTTCAATTTCTACTAAGTGTAGATCTCTAG 
AR MST 3 R GAGGGTTCCTAGAGATCTACACTTAGTAGAAATTGAAAGG 
AR MST Last F GAACCCTCAGCCCCAATTTCTACTAAGTGTAGAT 
AR MST Last R AAACATCTACACTTAGTAGAAATTGGGGCT 
HBB MST First F CACCGAATTTCTACTAAGTGTAGATTACTGA 
HBB MST First R CCATACCATCAGTAATCTACACTTAGTAGAAATTC 
HBB MST 2 F TGGTATGGGGCCAAAATTTCTACTAAGTGTAGATAAGTCC 
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HBB MST 2 R TAGGAGTTGGACTTATCTACACTTAGTAGAAATTTTGGCC 
HBB MST 3 F AACTCCTAAGCCAGAATTTCTACTAAGTGTAGATCAAGTG 
HBB MST 3 R CGTAAATACACTTGATCTACACTTAGTAGAAATTCTGGCT 
HBB MST Last F TATTTACGTAATATAATTTCTACTAAGTGTAGAT 
HBB MST Last R AAACATCTACACTTAGTAGAAATTATATTA 
NPY1R MST First F CACCGAATTTCTACTAAGTGTAGATAAGCCT 
NPY1R MST First R GTTTCCCGAGGCTTATCTACACTTAGTAGAAATTC 
NPY1R MST 2 F CGGGAAACTGCCCTAATTTCTACTAAGTGTAGATTTTGTT 
NPY1R MST 2 R GACCTGCAAACAAAATCTACACTTAGTAGAAATTAGGGCA 
NPY1R MST 3 F TGCAGGTCAGTGCCAATTTCTACTAAGTGTAGATGGCTGG 
NPY1R MST 3 R CTCGAGCGCCAGCCATCTACACTTAGTAGAAATTGGCACT 
NPY1R MST Last F CGCTCGAGCTCTCCAATTTCTACTAAGTGTAGAT 
NPY1R MST Last R AAACATCTACACTTAGTAGAAATTGGAGAG 
Fn DR F CacCGTAATTTCTACTGTTGTAGATgCgtcttcgaattcgaagacct 
Fn DR R aaacaggtcttcgaattcgaagacGcATCTACAACAGTAGAAATTAC 
ASCL1 c1 F AGATAGCTGGGTTTGTTGTTGCAG 
ASCL1 c1 R AAACCTGCAACAACAAACCCAGCT 
ASCL1 c2 F AGATCAAGGAGcgggagaaaggaa 
ASCL1 c2 R AAACttcctttctcccgCTCCTTG 
ASCL1 c3 F AGATgggagtgggtgggaggaaga 
ASCL1 c3 R AAACtcttcctcccacccactccc 
IL1RN c1 F AGATCGCAGATAAGAACCAGTTTG 
IL1RN c1 R AAACCAAACTGGTTCTTATCTGCG 
IL1RN c2 F AGATCAGGAGGGTGACTCAGGCTA 
IL1RN c2 R AAACTAGCCTGAGTCACCCTCCTG 
IL1RN c3 F AGATGCATCAAGTCAGCCATCAGC 
IL1RN c3 R AAACGCTGATGGCTGACTTGATGC 
Fn HBB g1 F 2 
CACCGTAATTTCTACTGTTGTAGATTACTGATGGTATGGGGCCA
A 




Fn HBB g2 F 2 CACCGTAATTTCTACTGTTGTAGATAAGTCCAACTCCTAAGCCAG 
Fn HBB g2 R 2 
AAACCTGGCTTAGGAGTTGGACTTATCTACAACAGTAGAAATTA
C 
Fn HBB g3 F 2 CACCGTAATTTCTACTGTTGTAGATCAAGTGTATTTACGTAATAT 
Fn HBB g3 R 2 
AAACATATTACGTAAATACACTTGATCTACAACAGTAGAAATTA
C 
ASCL1 crRNA 4 F AGATTTGTTGCAGTGCGTGCGCCT 
ASCL1 crRNA 4 R AAACAGGCGCACGCACTGCAACAA 
ASCL1 crRNA 5 F AGATtcccgCTCCTTGCAAACTCT 
ASCL1 crRNA 5 R AAACAGAGTTTGCAAGGAGcggga 
ASCL1 crRNA 6 F AGATctttctcccgCTCCTTGCAA 
ASCL1 crRNA 6 R AAACTTGCAAGGAGcgggagaaag 
HBB crRNA 4 F AGATGTAGCAATTTGTACTGATGG 
HBB crRNA 4 R AAACCCATCAGTACAAATTGCTAC 
HBB crRNA 5 F AGATGAGGGAGGGCTGAGGGTTTG 
HBB crRNA 5 R AAACCAAACCCTCAGCCCTCCCTC 
IL1RN crRNA 4 F AGATTCTGCATGTGACCTCCCATC 
IL1RN crRNA 4 R AAACGATGGGAGGTCACATGCAGA 
IL1RN crRNA 5 F AGATGTTTCTGCTAGCCTGAGTCA 
IL1RN crRNA 5 R AAACTGACTCAGGCTAGCAGAAAC 
IL1RN crRNA 6 F AGATGCCAGCATGAGGAGATGGGC 
IL1RN crRNA 6 R AAACGCCCATCTCCTCATGCTGGC 
A 2X 1F CACCGTAATTTCTACTGTTGTAGATCAAGGA 
A 2X 1R tctcccgCTCCTTGATCTACAACAGTAGAAATTAC 
A 2X 2F GcgggagaaaggaaTAATTTCTACTGTTGTAGATTTGTTG 
A 2X 2R ACGCACTGCAACAAATCTACAACAGTAGAAATTAttcctt 
A 2X 3F CAGTGCGTGCGCCTTAATTTCTACTGTTGTAGAT 
A 2X 3R aaacATCTACAACAGTAGAAATTAAGGCGC 
H1 H2 2X 1F CACCGTAATTTCTACTGTTGTAGATTACTGA 
H1 H2 2X 1R CCATACCATCAGTAATCTACAACAGTAGAAATTAC 
H1 H2 2X 2F TGGTATGGGGCCAATAATTTCTACTGTTGTAGATAAGTCC 
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H1 H2 2X 2R TAGGAGTTGGACTTATCTACAACAGTAGAAATTATTGGCC 
H1 H2 2X 3F AACTCCTAAGCCAGTAATTTCTACTGTTGTAGAT 
H1 H2 2X 3R aaacATCTACAACAGTAGAAATTACTGGCT 
H4 H5 2X 1F CACCGTAATTTCTACTGTTGTAGATGTAGCA 
H4 H5 2X 1R GTACAAATTGCTACATCTACAACAGTAGAAATTAC 
H4 H5 2X 2F ATTTGTACTGATGGTAATTTCTACTGTTGTAGATGAGGGA 
H4 H5 2X 2R CTCAGCCCTCCCTCATCTACAACAGTAGAAATTACCATCA 
H4 H5 2X 3F GGGCTGAGGGTTTGTAATTTCTACTGTTGTAGAT 
H4 H5 2X 3R aaacATCTACAACAGTAGAAATTACAAACC 
I4 I6 2X 1F CACCGTAATTTCTACTGTTGTAGATTCTGCA 
I4 I6 2X 1R AGGTCACATGCAGAATCTACAACAGTAGAAATTAC 
I4 I6 2X 2F TGTGACCTCCCATCTAATTTCTACTGTTGTAGATGCCAGC 
I4 I6 2X 2R CTCCTCATGCTGGCATCTACAACAGTAGAAATTAGATGGG 
I4 I6 2X 3F ATGAGGAGATGGGCTAATTTCTACTGTTGTAGAT 
I4 I6 2X 3R aaacATCTACAACAGTAGAAATTAGCCCAT 
A2 first F CACCGTAATTTCTACTGTTGTAGATCAAGGA 
A24 F GcgggagaaaggaaTAATTTCTACTGTTGTAGATTTGTTG 
A4H1 F CAGTGCGTGCGCCTTAATTTCTACTGTTGTAGATTACTGA 
H1H2 F TGGTATGGGGCCAATAATTTCTACTGTTGTAGATAAGTCC 
H2I4 F AACTCCTAAGCCAGTAATTTCTACTGTTGTAGATTCTGCA 
I4I6 F TGTGACCTCCCATCTAATTTCTACTGTTGTAGATGCCAGC 
I6 last F ATGAGGAGATGGGCTAATTTCTACTGTTGTAGAT 
A4I4 F CAGTGCGTGCGCCTTAATTTCTACTGTTGTAGATTCTGCA 
I6H1 F ATGAGGAGATGGGCTAATTTCTACTGTTGTAGATTACTGA 
H2 last F AACTCCTAAGCCAGTAATTTCTACTGTTGTAGAT 
H1 first F CACCGTAATTTCTACTGTTGTAGATTACTGA 
I6A2 F ATGAGGAGATGGGCTAATTTCTACTGTTGTAGATCAAGGA 
A4 Last F CAGTGCGTGCGCCTTAATTTCTACTGTTGTAGAT 
H2A2 F AACTCCTAAGCCAGTAATTTCTACTGTTGTAGATCAAGGA 
I4 first F CACCGTAATTTCTACTGTTGTAGATTCTGCA 
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A2 first R tctcccgCTCCTTGATCTACAACAGTAGAAATTAC 
A24 R ACGCACTGCAACAAATCTACAACAGTAGAAATTAttcctt 
A4H1 R CCATACCATCAGTAATCTACAACAGTAGAAATTAAGGCGC 
H1H2 R TAGGAGTTGGACTTATCTACAACAGTAGAAATTATTGGCC 
H2I4 R AGGTCACATGCAGAATCTACAACAGTAGAAATTACTGGCT 
I4I6 R CTCCTCATGCTGGCATCTACAACAGTAGAAATTAGATGGG 
I6 last R aaacATCTACAACAGTAGAAATTAGCCCAT 
A4I4 R AGGTCACATGCAGAATCTACAACAGTAGAAATTAAGGCGC 
I6H1 R CCATACCATCAGTAATCTACAACAGTAGAAATTAGCCCAT 
H2 last R aaacATCTACAACAGTAGAAATTACTGGCT 
H1 first R CCATACCATCAGTAATCTACAACAGTAGAAATTAC 
I6A2 R tctcccgCTCCTTGATCTACAACAGTAGAAATTAGCCCAT 
A4 Last R aaacATCTACAACAGTAGAAATTAAGGCGC 
H2A2 R tctcccgCTCCTTGATCTACAACAGTAGAAATTACTGGCT 
I4 first R AGGTCACATGCAGAATCTACAACAGTAGAAATTAC 
NT 1st F CacCGTAATTTCTACTGTTGTAGATcgacgc 
NT 1st R acccggcggcgtcgATCTACAACAGTAGAAATTAC 
NT 12 F cgccgggtcacaacTAATTTCTACTGTTGTAGATaaacgc 
NT 12 R ttggttcggcgtttATCTACAACAGTAGAAATTAgttgtg 
NT 23 F cgaaccaactcgcgTAATTTCTACTGTTGTAGATgcgagc 
NT 23 R atgggtgcgctcgcATCTACAACAGTAGAAATTAcgcgag 
NT 34 F gcacccattggaccTAATTTCTACTGTTGTAGATgcgtcc 
NT 34 R ggtcttgcggacgcATCTACAACAGTAGAAATTAggtcca 
NT 45 F gcaagacctatccaTAATTTCTACTGTTGTAGATccgtcg 
NT 45 R ccgcgaaccgacggATCTACAACAGTAGAAATTAtggata 
NT 56 F gttcgcggctgcagTAATTTCTACTGTTGTAGATatttat 
NT 56 R gcgtgccgataaatATCTACAACAGTAGAAATTActgcag 
NT last F cggcacgccgcaatTAATTTCTACTGTTGTAGAT 
NT last R aaacATCTACAACAGTAGAAATTAattgcg 
A 1st 1 F CacCGTAATTTCTACTGTTGTAGATCAAGGA 
 41 
A 1st 1 R tctcccgCTCCTTGATCTACAACAGTAGAAATTAC 
A 1st 2 F GcgggagaaaggaaTAATTTCTACTGTTGTAGATaaacgc 
A 1st 2 R ttggttcggcgtttATCTACAACAGTAGAAATTAttcctt 
A 2nd 1 F cgccgggtcacaacTAATTTCTACTGTTGTAGATCAAGGA 
A 2nd 1 R tctcccgCTCCTTGATCTACAACAGTAGAAATTAgttgtg 
A 2nd 2 F GcgggagaaaggaaTAATTTCTACTGTTGTAGATgcgagc 
A 2nd 2 R atgggtgcgctcgcATCTACAACAGTAGAAATTAttcctt 
A 3rd 1 F cgaaccaactcgcgTAATTTCTACTGTTGTAGATCAAGGA 
A 3rd 1 R tctcccgCTCCTTGATCTACAACAGTAGAAATTAcgcgag 
A 3rd 2 F GcgggagaaaggaaTAATTTCTACTGTTGTAGATgcgtcc 
A 3rd 2 R ggtcttgcggacgcATCTACAACAGTAGAAATTAttcctt 
A 4th 1 F gcacccattggaccTAATTTCTACTGTTGTAGATCAAGGA 
A 4th 1 R tctcccgCTCCTTGATCTACAACAGTAGAAATTAggtcca 
A 4th 2 F GcgggagaaaggaaTAATTTCTACTGTTGTAGATccgtcg 
A 4th 2 R ccgcgaaccgacggATCTACAACAGTAGAAATTAttcctt 
A 5th 1 F gcaagacctatccaTAATTTCTACTGTTGTAGATCAAGGA 
A 5th 1 R tctcccgCTCCTTGATCTACAACAGTAGAAATTAtggata 
A 5th 2 F GcgggagaaaggaaTAATTTCTACTGTTGTAGATatttat 
A 5th 2 R gcgtgccgataaatATCTACAACAGTAGAAATTAttcctt 
A 6th 1 F gttcgcggctgcagTAATTTCTACTGTTGTAGATCAAGGA 
A 6th 1 R tctcccgCTCCTTGATCTACAACAGTAGAAATTActgcag 
A 6th 2 F GcgggagaaaggaaTAATTTCTACTGTTGTAGAT 
A 6th 2 R aaacATCTACAACAGTAGAAATTAttcctt 
Fn 1 A1 orig F CACCGTAATTTCTACTGTTGTAGATCAAGGA 
Fn 1 A1 orig R tctcccgCTCCTTGATCTACAACAGTAGAAATTAC 
Fn 2 A1 orig F GcgggagaaaggaaTAATTTCTACTGTTGTAGATcgagcc 
Fn 2 A1 orig R aaggttatggctcgATCTACAACAGTAGAAATTAttcctt 
Fn 3 1-2 orig F ataaccttaggtgtTAATTTCTACTGTTGTAGATtgactt 
Fn 3 1-2 orig R gcggcttcaagtcaATCTACAACAGTAGAAATTAacacct 
Fn 4 2-3 orig F gaagccgcaacgttTAATTTCTACTGTTGTAGATtgcagc 
 42 
Fn 4 2-3 orig R acggacgtgctgcaATCTACAACAGTAGAAATTAaacgtt 
Fn 5 H5 orig F acgtccgtattgaaTAATTTCTACTGTTGTAGATTACTGA 
Fn 5 H5 orig R CCATACCATCAGTAATCTACAACAGTAGAAATTAttcaat 
Fn 6 H5 orig F TGGTATGGGGCCAATAATTTCTACTGTTGTAGATaggccg 
Fn 6 H5 orig R cgaaagctcggcctATCTACAACAGTAGAAATTATTGGCC 
Fn 7 4-5 orig F agctttcgaatcatTAATTTCTACTGTTGTAGATcaactg 
Fn 7 4-5 orig R acagcgcacagttgATCTACAACAGTAGAAATTAatgatt 
Fn 8 5-6 orig F tgcgctgtaagtcaTAATTTCTACTGTTGTAGATgacaga 
Fn 8 5-6 orig R tagtgcaatctgtcATCTACAACAGTAGAAATTAtgactt 
Fn 9 I9 orig F ttgcactagtcgtcTAATTTCTACTGTTGTAGATCAGGAG 
Fn 9 I9 orig R GAGTCACCCTCCTGATCTACAACAGTAGAAATTAgacgac 
Fn 10 I9 orig F GGTGACTCAGGCTATAATTTCTACTGTTGTAGAT 
Fn 10 I9 orig R aaacATCTACAACAGTAGAAATTATAGCCT 
Fn 5 I5 orig F acgtccgtattgaaTAATTTCTACTGTTGTAGATCAGGAG 
Fn 5 I5 orig R GAGTCACCCTCCTGATCTACAACAGTAGAAATTAttcaat 
Fn 6 I5 orig F GGTGACTCAGGCTATAATTTCTACTGTTGTAGATaggccg 
Fn 6 I5 orig R cgaaagctcggcctATCTACAACAGTAGAAATTATAGCCT 
Fn 9 H9 orig F ttgcactagtcgtcTAATTTCTACTGTTGTAGATTACTGA 
Fn 9 H9 orig R CCATACCATCAGTAATCTACAACAGTAGAAATTAgacgac 
Fn 10 H9 orig F TGGTATGGGGCCAATAATTTCTACTGTTGTAGAT 
Fn 10 H9 orig R aaacATCTACAACAGTAGAAATTATTGGCC 
Fn 1 H1 orig F CACCGTAATTTCTACTGTTGTAGATTACTGA 
Fn 1 H1 orig R CCATACCATCAGTAATCTACAACAGTAGAAATTAC 
Fn 2 H1 orig F TGGTATGGGGCCAATAATTTCTACTGTTGTAGATcgagcc 
Fn 2 H1 orig R aaggttatggctcgATCTACAACAGTAGAAATTATTGGCC 
Fn 5 A5 orig F acgtccgtattgaaTAATTTCTACTGTTGTAGATCAAGGA 
Fn 5 A5 orig R tctcccgCTCCTTGATCTACAACAGTAGAAATTAttcaat 
Fn 6 A5 orig F GcgggagaaaggaaTAATTTCTACTGTTGTAGATaggccg 
Fn 6 A5 orig R cgaaagctcggcctATCTACAACAGTAGAAATTAttcctt 
Fn 9 A9 orig F ttgcactagtcgtcTAATTTCTACTGTTGTAGATCAAGGA 
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Fn 9 A9 orig R tctcccgCTCCTTGATCTACAACAGTAGAAATTAgacgac 
Fn 10 A9 orig F GcgggagaaaggaaTAATTTCTACTGTTGTAGAT 
Fn 10 A9 orig R aaacATCTACAACAGTAGAAATTAttcctt 
Fn 1 I1 orig F CACCGTAATTTCTACTGTTGTAGATCAGGAG 
Fn 1 I1 orig R GAGTCACCCTCCTGATCTACAACAGTAGAAATTAC 
Fn 2 I1 orig F GGTGACTCAGGCTATAATTTCTACTGTTGTAGATcgagcc 
Fn 2 I1 orig R aaggttatggctcgATCTACAACAGTAGAAATTATAGCCT 
Fn 1 A1 Mut F CACCGTAATTCCTACTGTTGTAGGTCAAGGA 
Fn 1 A1 Mut R tctcccgCTCCTTGACCTACAACAGTAGGAATTAC 
Fn 2 A1 Mut F GcgggagaaaggaaTAATTCCTACTGTTGTAGGTcgagcc 
Fn 2 A1 Mut R aaggttatggctcgACCTACAACAGTAGGAATTAttcctt 
Fn 3 1-2 Mut F ataaccttaggtgtTAATTCCTACTGTTGTAGGTtgactt 
Fn 3 1-2 Mut R gcggcttcaagtcaACCTACAACAGTAGGAATTAacacct 
Fn 4 2-3 Mut F gaagccgcaacgttTAATTCCTACTGTTGTAGGTtgcagc 
Fn 4 2-3 Mut R acggacgtgctgcaACCTACAACAGTAGGAATTAaacgtt 
Fn 5 H5 Mut F acgtccgtattgaaTAATTCCTACTGTTGTAGGTTACTGA 
Fn 5 H5 Mut R CCATACCATCAGTAACCTACAACAGTAGGAATTAttcaat 
Fn 6 H5 Mut F TGGTATGGGGCCAATAATTCCTACTGTTGTAGGTaggccg 
Fn 6 H5 Mut R cgaaagctcggcctACCTACAACAGTAGGAATTATTGGCC 
Fn 7 4-5 Mut F agctttcgaatcatTAATTCCTACTGTTGTAGGTcaactg 
Fn 7 4-5 Mut R acagcgcacagttgACCTACAACAGTAGGAATTAatgatt 
Fn 8 5-6 Mut F tgcgctgtaagtcaTAATTCCTACTGTTGTAGGTgacaga 
Fn 8 5-6 Mut R tagtgcaatctgtcACCTACAACAGTAGGAATTAtgactt 
Fn 9 I9 Mut F ttgcactagtcgtcTAATTCCTACTGTTGTAGGTCAGGAG 
Fn 9 I9 Mut R GAGTCACCCTCCTGACCTACAACAGTAGGAATTAgacgac 
Fn 10 I9 Mut F GGTGACTCAGGCTATAATTCCTACTGTTGTAGGT 
Fn 10 I9 Mut R aaacACCTACAACAGTAGGAATTATAGCCT 
Fn 5 I5 Mut F acgtccgtattgaaTAATTCCTACTGTTGTAGGTCAGGAG 
Fn 5 I5 Mut R GAGTCACCCTCCTGACCTACAACAGTAGGAATTAttcaat 
Fn 6 I5 Mut F GGTGACTCAGGCTATAATTCCTACTGTTGTAGGTaggccg 
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Fn 6 I5 Mut R cgaaagctcggcctACCTACAACAGTAGGAATTATAGCCT 
Fn 9 H9 Mut F ttgcactagtcgtcTAATTCCTACTGTTGTAGGTTACTGA 
Fn 9 H9 Mut R CCATACCATCAGTAACCTACAACAGTAGGAATTAgacgac 
Fn 10 H9 Mut F TGGTATGGGGCCAATAATTCCTACTGTTGTAGGT 
Fn 10 H9 Mut R aaacACCTACAACAGTAGGAATTATTGGCC 
Fn 1 H1 Mut F CACCGTAATTCCTACTGTTGTAGGTTACTGA 
Fn 1 H1 Mut R CCATACCATCAGTAACCTACAACAGTAGGAATTAC 
Fn 2 H1 Mut F TGGTATGGGGCCAATAATTCCTACTGTTGTAGGTcgagcc 
Fn 2 H1 Mut R aaggttatggctcgACCTACAACAGTAGGAATTATTGGCC 
Fn 5 A5 Mut F acgtccgtattgaaTAATTCCTACTGTTGTAGGTCAAGGA 
Fn 5 A5 Mut R tctcccgCTCCTTGACCTACAACAGTAGGAATTAttcaat 
Fn 6 A5 Mut F GcgggagaaaggaaTAATTCCTACTGTTGTAGGTaggccg 
Fn 6 A5 Mut R cgaaagctcggcctACCTACAACAGTAGGAATTAttcctt 
Fn 9 A9 Mut F ttgcactagtcgtcTAATTCCTACTGTTGTAGGTCAAGGA 
Fn 9 A9 Mut R tctcccgCTCCTTGACCTACAACAGTAGGAATTAgacgac 
Fn 10 A9 Mut F GcgggagaaaggaaTAATTCCTACTGTTGTAGGT 
Fn 10 A9 Mut R aaacACCTACAACAGTAGGAATTAttcctt 
Fn 1 I1 Mut F CACCGTAATTCCTACTGTTGTAGGTCAGGAG 
Fn 1 I1 Mut R GAGTCACCCTCCTGACCTACAACAGTAGGAATTAC 
Fn 2 I1 Mut F GGTGACTCAGGCTATAATTCCTACTGTTGTAGGTcgagcc 
Fn 2 I1 Mut R aaggttatggctcgACCTACAACAGTAGGAATTATAGCCT 




SETD1A F  GCGTTGATATCAACAAGTTTACCCCCGCCGCCAC 






2.5 Plasmids list 
Table 2.2 - List of plasmids used in this study 
Name of plasmid Source 
Luc gRNA  (Kleinjan et al.) 
pTK Renilla (Kleinjan et al.) 
p8BSI (Kleinjan et al.) 
U6 no scaf (Kleinjan et al.) 
dCas9-VPR (Chavez et al.) 
AsCas12a  (Zetsche et al.) 
FnCas12a  (Zetsche et al.) 
LbCas12a  (Zetsche et al.) 




dAsCas12a VP64 Site 1 5AA linker Cloned 
dAsCas12a VP64 Site 2 5AA linker Cloned 
dCas9-SETD2 Cloned 
























2.6 qPCR primers 
Table 2.3 - List of qPCR primers used in this study 
qPCR primers Column1 Source 
ASCL1 qPCR F CGCGGCCAACAAGAAGATG Kleinjan et al. 2017 
ASCL1 qPCR R CGACGAGTAGGATGAGACCG Kleinjan et al. 2017 
HBB qPCR F AAG CTG CAC GTG GAT CCT GA 
Designed and 
calibrated 
HBB qPCR R ATT AGC CAC ACC AGC CAC CA 
Designed and 
calibrated 
IL1RN qPCR F GGAATCCATGGAGGGAAGAT Kleinjan et al. 2017 
IL1RN qPCR R TGTTCTCGCTCAGGTCAGTG Kleinjan et al. 2017 
NPY1R qPCR F CCATCGGACTCTCATAGGTTGTC Tak et al. 2017 
NPY1R qPCR R GACCTGTACTTATTGTCTCTCATC Tak et al. 2017 
AR qPCR F ATGGTGAGCAGAGTGCCCTATC Tak et al. 2017 
AR qPCR R ATGGTCCCTGGCAGTCTCCAAA Tak et al. 2017 
X5 qPCR F tcatgtgacctgccctctagt Buonomo lab 
X5 qPCR R caccctaccataatgcacca Buonomo lab 
TSIX qPCR F GACTTCTCTGCCCGTGAAAC Buonomo lab 


























Chapter 3 Generating Cas12a derived 
synthetic transcription factors  
 
3.1 Introduction 
The initial focus of the project was the generation of synthetic transcription factors, 
taking some of the advancements achieved using the Cas9 (Figure 3.1A) and 
translating these to Cas12a (Figure 3.1B). As previously described in Chapter 1, key 
advances have been made in the field of synthetic transcription factors, with 
adaptation of the Cas9 platform making transactivation of target genes highly 
tractable. Cas9 based synthetic transcription factors only require the generation of 
a unique gRNA for targeting a specific locus, in contrast to protein engineering 
required for zinc finger or TALE based approaches. Such synthetic Cas9-based 
transcription factors were obtained by first generating DNase inactive variants of 
Cas9 (dCas9) through single amino acid substitutions in the RuvC and HNH domains 
(Jinek et al., 2012), followed by the fusion of transactivation domains such as VP64 
to dCas9 to allow up-regulation of targeted genes (Maeder et al., 2013a). 
 
Here, we aim to build on this work by adapting more recently discovered CRISPR 
variants which possess interesting and improved properties compared to 
CRISPR/Cas9. In particular, Cas12a/Cpf1 has been demonstrated to possess the 
ability to process it’s own crRNA arrays (Fonfara et al., 2016), and does not require 
tracrRNA for the targeting of loci (Zetsche et al., 2015a). This feature of Cas12a 
facilitates the generation of multiple unique targeting crRNAs, with transcripts 
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being potentially able to up-regulate multiple target genes simultaneously. This in 
turn allows more loci to be targeted within a short length of DNA, when compared 
to Cas9 systems. This is of particular use in applications where size limitations 
present a barrier, such as the delivery of genetic material using the adeno-
associated virus. Finally, the ability to express multiple crRNAs from a single 
transcript presents applications focused on control and regulation, where it is 
desirable to have two or more actions directly coupled to one another, such as 





















Figure 3-1 - Diagrammatic representation of initial aims of Chapter 3 
Diagrammatic representation of the adaptation of (A) CRISPR/Cas9 and (B) Cas12a. First, amino acid 
substitutions enable inactivation of DNase activity and next effector domains such as the transactivation domain 
VPR can be fused to the catalytically inactive dCas9 to enable generation of a synthetic transcription factor. 
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3.2 Generation of dCas12a 
We generated DNase inactive variants of Cas12a derived from three different 
species. These Cas12a variants were chosen based on their clearly defined and 
relatively short PAM sequences, and their relatively high likelihood of binding 
DNA/chromatin in a mammalian cell context. Two of these variants, AsCas12a 
(derived from Acidaminococcus sp.) and LbCas12a (derived from Lachnospiraceae 
bacterium) were highlighted in the original paper by Zetsche et al. as having cleaved 
the human genome (Zetsche et al., 2015b). It was therefore hypothesised that, like 
Cas9, they had a high likelihood of being able to bind DNA when the DNase activity 
was abolished. Both the AsCas12a and LbCas12a variants were characterised as 
having a PAM sequence of ‘TTTN’. The third variant, FnCas12a (derived from 
Francisella tularensis subsp. novicida) was selected because it was characterised to 
have the shortest PAM sequence in the family ‘TTN’ as opposed to ‘TTTN’, and also 
showcased faint bands indicating cleavage of the human genome in cleavage assays 
reported by Zetsche et al.. Addgene plasmids for the mammalian codon-optimised 
variants of AsCas12a (#69982), FnCas12a (#69976) and LbCas12a (#69988) were a 
gift from Feng Zhang (Table 2.2). The plasmids were modified to generate DNase 
inactive variants of Cas12a, through a conserved amino acid substitution (Figure 
3.2B), previously reported to abolish cleavage (Zetsche et al., 2015b). We generated 
these amino acid substitutions corresponding to D908A for AsCas12a, D917A for 
FnCas12a, and D832A for LbCas12a using multichange isothermal mutagenesis 
(Mitchell et al., 2013) (Figure 3.2C). Primers were designed to enable amplification 
of Cas12a in two parts using the following primer pairs; As-OuterF + As Mut1R and 
As Mut1F + OuterR for the As variant, Fn-OuterF + Fn Mut1R and Fn Mut1F + 
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OuterR for the Fn variant, Lb-OuterF + Lb Mut1R and Lb Mut1F + OuterR for the Lb 
variant (Table 2.1). The primers were designed such that the amino acid 
substitution is incorporated by the reverse primer for the first amplicon and the 
forward primer for the second amplicon (Figure 3.2C). After PCR purification of 
these amplicons using a QIAquick PCR Purification Kit and digestion of the original 
plasmids with SbfI and BamHI to remove the original coding sequence, the 
amplicons were assembled with their respective linearised backbone, thus 





Figure 3-2 - Construction and expression of putative Cas12a-based synthetic transcription 
factors 
A) Diagrammatic representation of the initial project objectives. B) Amino acid sequence alignment 
using Clustal Omega was performed for the three chosen variants of Cas12a; As, Fn and Lb.  The 
conserved aspartic acid residue reported to abolish cleavage activity is highlighted in red and 
mutated to Alanine to abolish DNase activity. C) The cloning strategy for the generation of putative 
synthetic transcription factors. The amino acid substitution previously highlighted is introduced 
using multichange isothermal mutagenesis. After sequence verification the VPR transactivation 
domain was cloned to the 3ʹ-end of the coding sequence, using restriction ligation. D) Western Blot 
analysis using anti-HA antibody showing the putative synthetic transcription factors tagged with HA 
at the expected sizes in HEK293 transformed cells. Wild-type AsCpf1 was used as a positive control 







As  EIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHP-ETPIIGIDRGERNLI  915
Fn  DLIKDKRFTEDKFFFHCPITINFKSSG-ANKFNDEINLLLKEKANDVHILSIDRGERHLA  924
Lb  DVYKDKRFSEDQYELHIPIAINKCPKN-IFKINTEVRVLLKHDD-NPYVIGIDRGERNLL  839




































3.3 Generation of dCas12a-VPR C-terminal fusion proteins 
The dCas12a plasmids were sequence verified before the transactivation domain 
VPR (Chavez et al., 2015) was sub-cloned to the 3ʹ-end of the dCas12a coding 
sequence. The VPR domain was chosen, because it was demonstrated to be the 
most powerful single component transactivator domain in mammalian cells to date 
(Chavez et al., 2015). To generate this construct a traditional restriction ligation  
approach was used (Materials and Methods 2.1.9 and 2.1.2). First, the VPR domain 
was amplified with primers (VPR F + VPR R) (Table 2.1) designed to incorporate FseI 
and XhoI restriction sites, amplifying from the dCas9-VPR plasmid (Addgene 
#63798) (Table 2.2). The dCas12a plasmids and the amplicon were digested with 
FseI and XhoI. Subsequently the digested fragments were purified and ligated into 
the linearised dCas12a plasmids (Figure 3.2C). The resulting plasmids were 
sequence verified prior to protein expression analysis in transiently transfected 
HEK293 cells. The plasmids were transfected into HEK293 cells in a 24-well plate 
using Lipofectamine 2000 (ThermoFisher), with a non-transfected well serving as a 
mock transfection. The transiently transfected cells were incubated for 2 days at 
37°C and 5% CO2, before being washed with PBS and resuspended in SDS-PAGE 
sample buffer for Western Blot analysis (Materials and Methods 2.1.14) using 
mouse-derived anti-HA antibodies (Sigma HA-7; 019K4833). These antibodies bind 
to the retained HA tags within the dCas12a-VPR constructs (present in the original 
Cas12a plasmids) and enable visualisation of the HA-tagged proteins. The proteins 
could then be visualised after incubating the blot with anti-mouse HRP antibody. 
Specific bands of the predicted molecular weights of 213kDA, 213kDa and 205kDa 
for the As, Fn and Lb variants respectively were observed, along with the loading 
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control β-tubulin (51kDa) in all wells, as expected (Figure 3.2D). These results 
confirm that the full-length tagged proteins are successfully expressed in HEK293 
cells. The fainter bands of the dCas12a-VPR variants compared to the wild-type 
AsCas12a band could be either owing to incomplete transfer of the fusion proteins 
from the SDS-PAGE gel to the membrane due to lower transfer speed seen for 
larger proteins, or due to the HA-tag being hidden in the middle of the dCas12a-
VPR fusion variants, since the VPR domain was inserted to the 3ʹ-end of the HA tag. 
 
3.4 Screening functional activity of dCas12a-VPR C-terminal fusion 
proteins 
Having successfully expressed the putative synthetic transcription factors for all 
three variants of dCas12a, we proceeded to test their functional activity in 
mammalian cells. The initial screen was designed to utilise a previously published 
Firefly luciferase-encoding reporter plasmid (FF Luc) (Kleinjan et al., 2017), where 8 
repeats of 20-nucleotide binding sequences were flanked by the SpCas9 PAM 
sequence on the 3ʹ-end and the Cas12a PAM sequence on the 5ʹ-end (Figure 3.3A). 
Upon sequence verification of the reporter construct, 2 of the 8 repeats were 
shown to contain mutations. However, we decided to proceed with the construct 
for screening, as 6 consecutive repeats should still provide sufficient recruitment of 
transactivation domains to observe transactivation activity. This enabled us to 




First crRNAs were designed to enable targeting of the dCas12a-VPR variants to the 
Firefly Luciferase reporter plasmid. Due to the characterised PAM sequence of TTTN 
for the As and Lb variant and TTN for the Fn variant, the ‘TTTT’ PAM sequence was 
used 5ʹ to the repeat sequence. The crRNAs for each variant were generated by 
ligating annealed oligos into the BpiI linearised U6 No scaf vector (As luc g F + As luc 
g R for the As crRNA, Fn luc g F + Fn luc g R for the Fn crRNA and Lb luc g F + Lb luc g 
R for the Lb crRNA) , which would enable expression of the incorporated crRNA 
sequences from the human U6 Pol III promoter (Figure 3.3B). The oligos were 
designed with a conserved 20 nucleotide spacer sequence, to target the repeat 
binding sites on the FF Luc plasmid, whilst incorporating the structural direct repeat 
unique to each variant being screened at the 5ʹ-end. The direct repeat is unique for 
each variant and forms a hairpin which is recognised by the respective Cas12a 
variant. Finally, a single G was also included at the 5ʹ-end of each oligo, 
corresponding to the start of the transcript, to improve expression of the crRNAs 
from the Pol III promoter (Gao et al., 2017). 
 
The assay relied on the co-delivery of the reporter plasmid, alongside a control 
Renilla luciferase plasmid for normalisation of the activity. Each well in a 24-well 
plate of HEK293 cells was transiently transfected with the two luciferase plasmids 
alongside either a CRISPR derived transcription factor plasmid only (as a negative 
control), or the same plasmid and the respective targeting gRNA/crRNA plasmid 
(Figure 3.3B). We hypothesised that if the synthetic transcription factors were 
active, then the ratio of Firefly to Renilla luciferase would be considerably higher 
when the targeting gRNA/crRNA was present compared to when it was absent. The 
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Cas12a-derived putative synthetic transcription factors utilised the ‘TTTT’ PAM 
sequence, which fell within the initial characterisation by Zetsche et al. who 
described the PAM sequence as TTTN (Zetsche et al., 2015b). The transiently 
transfected HEK293 cells were incubated for two days at conditions previously 
described and washed with PBS, before addition of passive lysis buffer and 
incubation for 15 min at room temperature.  The samples were then transferred to 
a 96-well plate for imaging with the Modulus II Microplate Multimode Reader 
(PROMEGA). The results observed for the positive control dCas9-VPR confirmed 
that the assay itself was working as expected, showing a significant increase in the 
ratio of Firefly to Renilla luciferase when the targeting gRNA was present. However, 






Figure 3-3 - Design and screening of putative dCas12a (c-terminally tagged) synthetic 
transcription factors  
A) Diagrammatic representation of the reporter construct used in the dual luciferase assay, 
containing the repeated binding sites (blue) and the adjacent Cas12a (red) and Cas9 (purple) PAM 
sequences. The ratio of the two luciferase activities (expressed from separate plasmids) was read to 
assess the functional activity of the putative synthetic transcription factor in up-regulating the 
targeted Firefly Luciferase. B) Diagrammatic representation of the experimental setup to screen for 
activity of the putative synthetic transcription factors. The crRNA vectors were generated by 
linearising the U6 vector with BpiI before ligating the annealed oligos. All wells were transfected 
with the Luciferase constructs (pTK Renilla Luciferase and p8BSI minP GL4), the dCas12a-VPR 
constructs with or without their respective crRNAs, or dCas9-VPR with or without a targeting gRNA 
to serve as positive control. The Firefly and Renilla luciferase activities were measured 48 h post 
transfection. C) Graph showing the ratios of the Firefly to Renilla luciferase for the samples with the 
targeting crRNA/gRNA relative to the respective samples without a targeting crRNA/gRNA (n = 3) 
and error bars showing standard deviation.  
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3.5 Screening of unique targeting crRNAs 
To understand the lack of discernible activity in the dCas12a-VPR variants, the first 
factor considered was the spacer sequence and the specific location of the crRNAs, 
with previous work showing that positioning in particular can have a large effect on 
activity (Gilbert et al., 2014). As previously mentioned, 2 of the 8 repeats of the 
targeted reporter construct were mutated in the dual luciferase assay, however 
they still preserved the ‘TTTT’ PAM sequence. Additionally, a third sequence 
provided a targeting sequence with a ‘TTTT’ PAM immediately downstream of the 
tandem repeats (Figure 3.4A). As such this presented 3 unique targeting sequences, 
allowing for a diversity of spacer sequences and positions to be screened. Screening 
of unique crRNAs focussed on the As or Lb variants of Cas12a-VPR, because they 
were characterised to have robust cleavage activity in mammalian cells (Zetsche et 
al., 2015b). The three crRNAs for both As and Lb were generated by restriction 
ligation of annealed oligos (Table 3.1) into a Bpi1 digested pU6 expression vector 
and subsequently sequence verified (Materials and Methods 2.1.1, 2.12 and 2.1.9). 
The dual luciferase assay was performed as previously described, however for this 
screen, the three newly constructed targeting crRNAs (each on separate plasmids) 
were co-transfected alongside their respective dCas12a-VPR variant. After 2 days, 
the cells were washed with PBS and the luciferase assay was performed (Materials 
and Methods 2.3.1). The results once again demonstrated that the assay was 
working as expected, with the dCas9-VPR showing robust up-regulation. However, 
the dCas12a-VPR variants showed no significant up-regulation (Figure 3.4B), 
suggesting it may not be the crRNA composition or target location within the 




Table 3.1 - 3 unique crRNAs for luciferase targeting 
crRNA name Forward oligo Reverse oligo 
As g1 As g1 F As g1 R 
As g2 As g2 F As g2 R 
As g3 As g3 F As g3 R 
Lb g1 Lb g1 F Lb g1 R 
Lb g2 Lb g2 F Lb g2 R 
Lb g3 Lb g3 F Lb g3 R 
















Figure 3-4 - Screening alternative targeting crRNAs 
A) Diagrammatic representation of the unique locations being targeted. After three unique crRNAs 
were generated for the As and Lb Cas12a variants, the crRNAs were co-transfected alongside the 
two reporter plasmids and dAsCas12a-VPR or dLbCas12a-VPR. B) Results from dual luciferase assay, 
screening activity of dAsCas12a-VPR and dLbCas12a-VPR using the unique crRNAs, and dCas9-VPR 
with the original gRNA as a positive control (n = 3). All conditions are internally normalised to the 
respective constructs without the targeting crRNA/gRNA, with error bars showing standard 

























































C-terminally tagged with 




3.6 Generation of VPR-dCas12a N-terminal fusion proteins 
Next, we investigated if the observed inactivity of dCas12a-VPR variants could be a 
result of the location of the effector protein tagged to the C-terminal of the 
dCas12a protein. We visualised the crystal structure of the active AsCas12a protein 
(Yamano et al., 2016) using PyMOL and found that the C-terminus and the N-
terminus were exposed at opposite sides of the protein (Figure 3.5A). This 
suggested that any detrimental effect of C-terminal fusion of Cas12a with the VPR 
domain through misfolding can potentially be ameliorated by N-terminal fusion. 
This strategy was supported by the success with dCas9, where tagging VP64 domain 
to the N-terminus preserved the ability to activate target genes (Duellman et al., 
2017). To test this hypothesis, we N-terminally tagged dAsCas12a using Gibson 
assembly (Materials and Methods 2.1.13). The 5ʹ-end of the dAsCas12a coding 
sequence was excised from the dAsCas12a plasmid by digesting with KpnI and SbfI, 
generating a linearized plasmid backbone. Then, the VPR domain was amplified 
from dCas9-VPR (F primer VPR + R VPR AsCpf1) and the 5ʹ-end of the coding 
sequence for dAsCas12a was amplified from the dAsCas12a plasmid (N term As F + 
N term As R) (Figure 3.5B). The VPR domain was amplified using primers designed 
to incorporate the flexible glycine serine rich linker on the 3ʹ-end of the VPR 
domain. Furthermore, the primers also incorporated 40bp of homology to the 
linearized plasmid and the dAsCas12a-derived amplicon. Gibson assembly was 
performed to generate the N-terminally VPR tagged variant of dAsCas12a, with a 
flexible linker between the two proteins (Figure 3.5B). The assembled construct was 
sequence verified prior to functional activity screening. 
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3.7 Screening of N- and C-terminally VPR tagged dAsCas12a fusion 
proteins 
The N-terminally tagged VPR-dAsCas12a was transfected alongside the C-terminally 
tagged dAsCas12a-VPR variant, each co-transfected alongside the first targeting 
crRNA tested (Results 3.4). The results were normalised to delivery without a 
targeting gRNA/crRNA. After 2 days, the cells were washed with PBS and the 
luciferase assay was performed.  The dual luciferase assay demonstrated that whilst 
the dCas9-VPR positive control was able to up-regulate Firefly luciferase relative to 
Renilla luciferase, neither the C-terminal nor the N-terminal tagged variant of 
dAsCas12a-VPR fusion proteins showed activation (Figure 3.5C). 
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Figure 3-5 - Design and testing of N-terminally tagged dAsCas12a-based synthetic 
transcription factors (VPR) 
A) Schematic representation of wild-type AsCas12a, with the C-terminus and N-terminus of the 
protein highlighted. B) Diagrammatic representation of the cloning strategy to generate the N-
terminally tagged VPR-dAsCas12a. C) Results of dual luciferase assay screening in HEK293 cells for 
activity of the N-terminally tagged VPR-dCas12a, alongside the C-terminally tagged dCas12a-VPR and 


















































































3.8 Generation of internally tagged dAsCas12a-VP64 
As a final strategy, protein engineering involving the insertion of shorter VP64 
domains into exposed loops of dAsCas12 was considered, with the shorter VP64 
domain chosen to minimise potential disruption caused by insertion. This strategy 
was based on a report were oestrogen receptor domains were inserted at several 
locations of the Cas9 protein, enabling oestrogen-dependent Cas9 cleavage that is 
dependent on conformational changes in the oestrogen receptor domain (Oakes et 
al., 2016). They specifically noted that the successful insertions were 
disproportionately found around flexible loops. These findings suggest that it may 
be possible to insert domains within a related CRISPR homing endonuclease, 
without compromising the activity of either the homing endonuclease or the 
inserted domains. As such, we explored the protein structure of AsCas12a and 
identified two candidate loci with exposed flexible loop regions (Figure 3.6A). 
Instead of a full length VPR domain, this strategy centred upon inserting a shorter 
VP64 domain, which would typically have reduced activity, but could also decrease 
the likelihood of compromising the folding and structure of the dAsCas12a protein 
it would be inserted into. These constructs were generated using Gibson assembly 
(Materials and Methods 2.1.13), first digesting and removing the 3ʹ-end of the 
dAsCas12a coding sequence, before reconstituting the coding sequence, using 
three amplicons with overlapping overhangs (Figure 6B). Two of these three 
amplicons were derived from the N-terminal portion (As PmlI F + As Site 1 PmlI R 
for site 1 and As PmlI F + As Site 2 PmlI R for site 2) and C-terminal portion (As Site 1 
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BamHI F + As BamHI R for site 1 and As Site 2 BamHI F + As BamHI R for site 2) of 
the original dAsCas12a vector. The final amplicon corresponding to the VP64 
domain was amplified from the dCas9-VPR vector (VP64 Site1 5AA F + VP64 Site1 
5AA R for site 1 and VP64 Site2 5AA F + VP64 Site2 5AA R for site 2). The primers 
used for amplification of the VP64 domain incorporated flexible 5AA linkers and 
40bp of homology to the dAsCas12a amplicons (Figure 3.6B). 
 
 
3.9 Screening of internally tagged dAsCas12a fusion proteins 
After sequence verification, the internally tagged dAsCas12a-VP64 variants were 
transfected into HEK293 cells alongside the dCas9-VPR as positive control. The 
constructs delivered without a targeting gRNA/crRNA served as negative controls. 
After 2 days, the cells were washed with PBS and the luciferase assay was 
performed. The results showed no significant upregulation for either of the two 
dAsCas12a variants with VP64 insertions at different sites, but significant up-





Figure 3-6 - Design and screening of internal [VP64] tagged dAsCas12a-based synthetic 
transcription factors 
A) Schematic representation of wild-type AsCas12a, with the flexible loops targeted for VP64 
insertion at site 1 and site 2 highlighted. B) Diagrammatic representation of the cloning strategy to 
generate the two internally tagged dAsCas12a-VP64 variants. C) Results of dual luciferase 
assay screening for Site 1 or Site 2 internally tagged dAsCas12a-VP64 variants, with dCas9-VPR 


















































































































3.10 Screening an alternate internally tagged fusion proteins 
Whilst these insertion sites had not resulted in active dCas12a-derived synthetic 
transcription factors, findings from a collaborator suggested that an alternative 
insertion site could enable generation of an active synthetic transcription factor 
(Dominguez-Monedero and Davies, 2018). Similar to the work by Oakes et al. 
(Oakes et al., 2016), Dominguez-Monedero and colleagues identified tamoxifen-
inducible activity of Cas12a variants when an oestrogen receptor was inserted 
within AsCas12a. We generated a new plasmid with VP64 inserted, with no flanking 
linkers, into the exposed flexible loop identified by Dominguez-Monedero et al. 
(Figure 3.7A), using the same Gibson assembly strategy previously described (Figure 
6B). As before, the N-terminal fragment of dAsCas12a was amplified (Outer Alaz As 
F + Inner Alaz As R), as was the C-terminal fragment (Inner Alaz As F + Outer Alaz As 
R). VP64 was amplified (VP64 Alaz As F + VP64 Alaz As R) with primers designed to 
incorporate 20bp overhangs with the N-terminal and C-terminal dAsCas12a 
amplicons. dAsCas12a was digested with SbfI and PmlI and run on a gel. The 
linearised plasmid backbone gel extracted (Materials and Methods 2.1.11) and 
Gibson assembly (Materials and Methods 2.1.13) was performed with the three 
purified amplicons. 
 
After sequence verification, this construct was transfected alongside the N-
terminally tagged dAsCas12a-VPR and dCas9-VPR serving as a positive control into 
HEK293 cells. After 2 days, the cells were washed with PBS and the luciferase assay 
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was performed. The dual luciferase assay was performed as previously described. 
However, we observed no transactivation with the dAsCas12a constructs (Figure 
3.7B). 
 
Taken together these results strongly suggest that the point of failure for these 
putative synthetic transcription factors was not likely the positioning or 




























































Figure 3-7 - Design and screening of an alternative variant of internal [VP64] tagged dAsCas12a-
based synthetic transcription factors (based on collaboration work with Davies group) 
A) Schematic representation of wild-type AsCas12a with the original flexible loops targeted for VP64 
insertion at site 1 and site 2 highlighted, alongside the alternative site recommended by a collaborator. B) 
Results of dual luciferase assay screening for dAsCas12a-VP64 variant tagged at an alternative site, with 
N-terminally tagged VPR-dAsCas12a serving as a negative control and dCas9-VPR serving as a positive 
control (n = 3). Error bars display the standard deviation. 
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3.11 Modification of PAM sequence and screening with dAsCas12a 
variants 
With none of the protein engineering strategies proving successful, we focussed on 
dissecting the importance of the targeting sequence and more specifically the 
chosen PAM sequence. As previously highlighted, Zetsche et al. had characterised 
the PAM sequence as TTTN for As and Lb variants and TTN for the Fn variant 
(Zetsche et al., 2015a). However, subsequent publications suggested that this may 
represent a subtle mischaracterisation, with Leenay et al. performing a 
comprehensive screen with the DNase inactive variant of FnCas12a that showed 
the PAM sequence for Fn was better represented by the motif ‘TTV’ (with V 
standing for any nucleotide, but T) (Leenay et al., 2016). This preference of V for the 
3ʹ-end nucleotide within the PAM sequence was also shown to translate to 
AsCas12a and LbCas12a by Kim et al. who observed a preferred PAM sequence of 
‘TTTV’ for both variants (Kim et al., 2017). This offered a compelling hypothesis 
explaining why none of the previously described protein engineering strategies 
were successful, as the dual luciferase screen had relied upon a PAM sequence of 
‘TTTT’. As such a new crRNA was designed and constructed for screening the C-
terminally and N-terminally VPR tagged dAsCas12a variants. The target sequence 
was moved by a single nucleotide at the 3ʹ-end on the targeted reporter plasmid, to 
provide a PAM sequence of ‘TTTC’ (Figure 3.8A). The corresponding crRNA vector 
was generated by annealing crRNA oligos (Alt PAM As Luc F + Alt PAM As Luc R) 
(Table 2.1) and ligating into a gel extracted BpiI digested U6 no scaf vector 
(Materials and Methods 2.1.1, 2.1.2 and 2.1.11). 
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Using this new crRNA for the As variants, we re-screened both the C-terminally and 
N-terminally tagged dAsCas12a-VPR using the dual luciferase assay. We were now 
able to see robust up-regulation for both constructs, with comparable up-
regulation to dCas9-VPR, with a mean of 48- and 128-fold increase for the C-
terminally and N-terminally tagged variants, respectively, compared to a mean 89-
fold increase for the positive control dCas9-VPR (Figure 3.8B). When a Welch’s t-
test was performed, no significant difference in activity between the C-terminally 

























































Figure 3-8 - Screening N-terminally tagged dAsCas12a VPR against TTTC PAM 
A) Diagrammatic representation of the dual luciferase assay, highlighting the modified target 
sequence utilising the ‘TTTC’ PAM sequence. B) Results of dual luciferase assay screening activity for 
dAsCas12a- variants C-terminally and N-terminally tagged with VPR and targeted with the alternative 
crRNA, with dCas9-VPR serving as a positive control (n = 3). Error bars display the standard deviation. 
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3.12 Conclusion and discussion 
A number of protein strategies were attempted for the generation of Cas12a 
derived synthetic transcription factors, however the PAM sequence appeared to be 
the critical bottleneck in development. These challenges highlight the importance 
improved representations of the binding/cleavage capabilities of CRISPR effectors 
(Leenay et al., 2016). Such approaches help to ameliorate the challenges that 
emerge when describing a PAM sequence using letters, which invariably lead to a 
conflict between flexibility (describing non-canonical PAM sequences) and 
stringency (avoiding inclusion of PAM sequences that appear to show no significant 
binding/cleavage).  
 
In the preceding work we used a dual luciferase assay to show successful 
generation of two different dAsCas12a-derived synthetic transcription factors 
employing two unique strategies for generation (C-terminal and N-terminal 
tagging). This shows that dCas12a is able to tolerate the fusion of effector domains 
to the N-terminus as well as the C-terminus of the protein, similar to what has been 
observed for dCas9 dCas9 (Duellman et al., 2017). We have also been able to 
confirm, what was subsequently published, that AsCas12a disfavours a T at the 3ʹ-
position of the PAM sequence in mammalian cells, but permits a target sequence of 
TTTC when targeting a plasmid within HEK293 cells (Kim et al., 2017). Moving 
forward, we will look into further characterising the generated synthetic 
transcription factors, giving particular attention to the remaining two Cas12a 
variants (Fn and Lb) and screening for activity when targeting endogenous 
promoters. 
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Chapter 4 Expanding and characterising the 
Cas12a tool 
4.1 Introduction 
Work published by Tak et al. has shown the capacity of both dAsCas12a-VPR and 
dLbCas12a-VPR to enable transactivation of target endogenous genes in mammalian cells 
(Tak et al., 2017). They also demonstrate significantly higher transactivation can be 
achieved by delivering pools of multiple crRNAs targeting a single gene. However, their 
work only focusses on two Cas12a variants and also does not seek to address the question 
of the level of orthogonality observed between these two different variants. To the best of 
our knowledge, the question of orthogonality between different Cas12a variants has yet to 
be explored in the literature and no published work has shown that FnCas12a can be 
converted into a synthetic transcription factor. In the following chapter we aimed to test 
whether all three variants of Cas12a tested (As, Fn and Lb) could be converted into 
synthetic transcription factors and enable transactivation in a mammalian context when a 
modified ‘TTTV’ PAM sequence was targeted. As orthogonality has been demonstrated 
between Cas9-derived from different species (Esvelt et al., 2013) (Gao et al., 2016), it is 
reasonable to hypothesise that Cas12a variants from different species may also operate 
orthogonally. The crRNA that targets the Cas12a protein is composed of a direct repeat 
sequence upstream of a spacer sequence (Figure 4.1a). The direct repeat sequence forms a 
stem loop and interacts with the Cas12a protein and the spacer sequence confers targeting 
specificity and can hybridise with the associated DNA sequence. If two Cas12a variants 
were orthogonal then the direct repeat derived from one of the species would only interact 
and enable targeting for the native protein variant, not the second variant and this would 




Figure 4-1 - Screening of three variants of dCas12a-VPR synthetic transcription factors 
against TTTC PAM 
A) Diagram showing the composition of the crRNA. The crRNA is composed of a structural direct 
repeat at the 5’ end, which interacts with the Cas12a and the spacer sequence encoding the 
targeting sequence. B) Diagram representing orthogonality between two different dCas12a-VPR 




Due to the applications dependent upon orthogonality (described in Chapter 1) we also 
screened for the orthogonality of the different dCas12a-VPR variants, specifically testing 
whether the three different variants demonstrated significant activity when targeted with a 
crRNA derived from one of the remaining two species (e.g dAsCas12a-VPR targeted by an 
Fn or Lb crRNA). Finally we also aimed to test if some of the effects observed for As and Lb 
variants (transactivation of endogenous genes and improved activity when multiple crRNAs 
















4.2 Screening dFnCas12a-VPR and dLbCas12a-VPR against a TTTC 
PAM  
Having demonstrated in chapter 3 that dAsCas12a-VPR was able to transactivate a Firefly 
luciferase when targeting the PAM sequence ‘TTTC’, we next determined whether 
dFnCas12a-VPR and dLbCas12a-VPR were also able to transactivate the targeted Firefly 
luciferase when a ‘TTTC’ PAM sequence was targeted (Figure 4.2A). To test this a new 
crRNA was designed and generated for each dCas12a-VPR variant, utilising the same spacer 
sequence previously used for screening dAsCas12a-VPR (described in chapter 3). These 
crRNAs were generated from annealed oligos containing the respective direct repeat and 
spacer sequences (Alt PAM Fn Luc F + Alt PAM Fn Luc R and Alt PAM Lb Luc F + Alt PAM Lb 
Luc R) (Table 2.1), before ligating these into a Bpi1 digested pU6 no scaf plasmid, to enable 
expression of the crRNAs. After sequence verification of these alternative crRNAs, the 
plasmids were transfected into HEK293 cells with their respective dCas12a-VPR plasmids, 
and the Firefly and Renilla Luciferase reporter plasmids for activity screening. These two 
conditions were screened alongside dAsCas12a-VPR (C-terminally tagged) and dCas9-VPR, 
serving as positive controls, with all conditions being compared to the respective synthetic 
transcription factors without a targeting gRNA/crRNA as an internal negative control. As 
previously described, the dual luciferase assay was performed 2 days post transfection. The 
results confirmed that dAsCas12a-VPR was able to robustly transactivate the targeted 
Firefly Luciferase (Figure 4.2B), with a Welch’s t-test showing significant transactivation had 
been achieved (P = 0.0013). Furthermore, we also observed significant transactivation for 
the Fn (P = 0.02) and Lb (P = 0.04) variants alongside the dCas9-VPR positive control. These 
results were of particular interest, as previous studies had suggested that FnCas12a was 
unable to cleave DNA in mammalian cells (a finding later refuted (Tóth et al., 2018)). 
Furthermore, the Fn variant has been characterised to have a shorter PAM sequence of 
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‘TTV’ rather than ‘TTTV’ for the As and Lb variants, meaning this variant can target genomic 
loci more densely. Denser targeting aids a variety of applications, where there are 
restrictions on the number of available targeting sites (such as when the targeting window 
is constrained or multiple promoters all need to be targeted) or where the targeting of 
more sites is desirable (if multiple crRNAs show higher transactivation or synergy). 
 
 
Figure 4-2 - Screening of three variants of dCas12a-VPR synthetic transcription factors 
against TTTC PAM 
A) Diagrammatic representation of the dual luciferase assay. The repeated binding sites are shown 
in blue, with the targeted ‘TTTC’ PAM sequence shown in orange. B) Graph showing the ratios of the 
Firefly to Renilla luciferase for the samples with the targeting crRNA/gRNA relative to the respective 
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4.3 Screening for orthogonality between dCas12a-VPR variants 
Having demonstrated dCas12a-VPR derived from three different species were able to 
induce robust transactivation, we next explored the orthogonality and fidelity of each 
variant relative to one another. The question of orthogonality specifically seeks to 
determine whether two variants will show activity with a crRNA specific to its own species, 
but not a crRNA derived from the other species. For example, if dAsCas12a-VPR only 
showed activity when delivered with a crRNA possessing the As derived direct repeat, not 
with a crRNA possessing the Fn derived direct repeat and dFnCas12a-VPR only showed 
activity when delivered with a crRNA possessing the Fn derived direct repeat, these would 
be described as orthogonal. The question of fidelity seeks to explore whether an individual 
variant only displays significant activity when delivered with a crRNA derived from its own 
species and not from crRNA derived from different species.  
 
As the direct repeat sequence for all three crRNAs was highly conserved, with a difference 
of only 1-3 bp localised to the hairpin loop (Figure 4.3A), we hypothesised that there may 
be some cross-reactivity between the different dCas12a-VPR/crRNA pairs. We screened the 
ability of each dCas12a-VPR variant to transactivate a targeted reporter gene when co-
transfected with crRNAs with a direct repeat derived from another species compared to 









Figure 4-3 - Design for orthogonality screen of dCas12a-VPR variants 
A) Minimal free energy structure of direct repeat sequences derived from As, Fn and Lb species 
predicted using RNA fold. The 5ʹ to 3ʹ sequence composition of the hairpin loop is shown beneath 
the predicted structure and unique nucleotides are highlighted with blue asterisk B) Diagrammatic 
representation of the combinations of dCas12a-VPR and targeting crRNAs to be screened using the 


















































To test for orthogonality, each dCas12a-VPR variant was transfected with the Firefly and 
Renilla Luciferase reporter plasmids into HEK293 cells alongside each crRNA to test all 
possible dCas12a-VPR/crRNA combinations (Figure 4.3B). Each dCas12a-VPR variant was 
also transfected without a targeting crRNA to serve as a negative control. Two days after 
transfection the dual luciferase assay was performed. For the purposes of screening we 
used an ordinary one-way ANOVA, setting significance at P = 0.05. When performing a 
Tukey’s multiple comparison test we observed significant transactivation over the negative 
control (no crRNA) for dAsCas12a-VPR and dFnCas12a-VPR when targeted with their own 
crRNAs (P = 0.0003 and P = 0.006 respectively) (Figure 4.4A). However, for dLbCas12a-VPR 
the P value 0.051 lay just below the threshold of significance. We were able to see that 
dAsCas12a-VPR was also able to induce significant transactivation when targeted by the Fn 
crRNA (P = 0.005), which may in part be explained by the minimal difference in sequence 
composition for the As and Fn crRNAs direct repeat (Figure 4.3A). We could see high fidelity 
for the dFnCas12a-VPR variant, with a significantly higher transactivation seen when the 
construct was delivered with the Fn crRNA compared to the As crRNA (P = 0.01) or the Fn 
crRNA compared to the Lb crRNA (P = 0.008). We also observed that when assessing 
dLbCas12a-VPR delivered with Lb crRNA compared to As or Fn crRNA, we were able to see 
close to significantly higher transactivation for the Lb crRNA condition (0.054 and 0.052 





Figure 4-4 - Results for orthogonality screen of dCas12a-VPR variants 
A) Graphs showing the relative expression of each of the three dCas12a-VPR variants screened for 
activity using the dual luciferase assay (n = 3). Each dCas12a-VPR variant was screened with crRNAs 
utilising a direct repeat derived from each of the respective species alongside screening with no 
crRNA as a negative control. Relative expression for each individual dCas12a-VPR variant is 
normalised to the no crRNA condition set to a value of 1. Error bars display the standard deviation. 
 B) Heatmap representing the activity of each of the three different synthetic transcription factors 
paired with each of the three crRNAs as well as no crRNA. The darker squares represent higher 























































































































































4.4 Targeting dFnCas12a-VPR to endogenous mammalian promoters  
Having demonstrated that dFnCas12a-VPR was able to transactivate a plasmid-based 
reporter, we next explored its ability to transactivate endogenous genes. At this time Tak et 
al. had published work showing that robust transactivation could be achieved for three 
different genes; AR, HBB and NPY1RN when targeting dLbCas12a-VPR to their promoters. 
We decided to utilise the same targeting crRNA arrays screened by Tak et al. (Tak et al., 
2017), but substituting the Lb derived direct repeats for Fn derived direct repeats, to 
enable screening of activity for dFnCas12a-VPR (Figure 4.5A). Oligo pairs were designed for 
constructing each array (Table 4.1), incorporating an 8bp overhang between each oligo pair 
to facilitate ligation. Each of the three crRNA arrays were constructed and sequence 
verified before being subsequently transfected into HEK293 cells alongside dFnCas12a-VPR, 
with dFnCas12a-VPR only serving as a negative control for each target gene. Three days 
post transfection, total RNA was extracted from each sample and 1µg was used to 
synthesize cDNA using oligo dT(20) primers (further described in Materials and Methods – 
2.3.2). 1µl of the generated cDNA was used for qRT-PCR analysis of the target gene and 
normalised to reference gene GAPDH (Figure 4.5B). The results were then analysed, 
performing a Welch’s t test to compare the DDCT values between the array conditions and 
the negative control (dFnCas12a-VPR only) (Materials and Methods 2.3.2). We observed 
highly significant transactivation was achieved for all three genes; P = 0.001 for AR, P = 
0.004 for HBB and P = 0.003 for NPY1R. Of note, whilst significant transactivation was 
achieved for all three arrays, the average fold up-regulation was substantially higher for 







Table 4.1 - Fn adapted Tak arrays 
AR array HBB array NPY1RN array 
First AR MST F HBB MST First F NPY1R MST First F 
First AR MST R HBB MST First R NPY1R MST First R 
AR MST 2 F HBB MST 2 F NPY1R MST 2 F 
AR MST 2 R HBB MST 2 R NPY1R MST 2 R 
AR MST 3 F HBB MST 3 F NPY1R MST 3 F 
AR MST 3 R HBB MST 3 R NPY1R MST 3 R 
AR MST Last F HBB MST Last F NPY1R MST Last F 
AR MST Last R HBB MST Last R NPY1R MST Last R 
















Figure 4-5 - Screening Tak et al. 3-crRNAs arrays with Fn direct repeats 
A) Diagrammatic representation of the targeting of dFnCas12a-VPR to endogenous AR, HBB and 
NPY1R promoters in HEK293 cells, alongside the 3-crRNA arrays used for targeting of the respective 
promoters. B) Diagram showing the assembly strategy for construction of the crRNA arrays. C) The 
crRNA arrays for each gene were transfected alongside dFnCas12a-VPR into HEK293 cells. Graphs 
show qRT-PCR data for relative expression of the AR, HBB or NPY1R transcripts, with dFnCas12a-VPR 
only (dFV only) serving as a negative control, with the mean for the negative control being set to 1 























































































































4.5 Screening individual crRNAs for activity against endogenous genes 
Having shown that robust transactivation could be achieved for dFnCas12a-VPR when 
targeting endogenous genes, we next sought to address two questions. 1) Could we 
identify more genes that demonstrated higher fold upregulation, to improve the signal to 
noise ratio for subsequent experiments where reduced transactivation may be expected? 
2) Could we observe significant transactivation when targeting dFnCas12a-VPR to a 
promoter using a single crRNA? To try and address these questions two endogenous 
promoters, driving expression of ASCL1 and IL1RN, were selected for targeting. These 
genes were chosen as they had previously shown high levels of transactivation using dCas9-
VPR in the Rosser lab (Kleinjan et al., 2017). Three crRNAs were designed to target each 
promoter region (Figure 4.6A). The crRNAs were constrained to a window of 50 to 300 
nucleotides upstream of the transcription start site (TSS) for each gene, based on work by 
Gilbert et al. in 2014 where they had tiled a Cas9 derived synthetic transcription factor 
across multiple promoter regions and observed highest activity when gRNAs targeted a 
window of 50 to 400 nucleotides upstream of the TSS (Gilbert et al., 2014). The TSS for 
each gene was identified using CAGE-Seq data curated by the FANTOM5 project 
(Abugessaisa et al., 2017). The crRNAs selected within this window were designed to target 
the characterised FnCas12a ‘TTV’ PAM sequence (Zetsche et al., 2015a). As subsequent 
work was expected to focus on dFnCas12a-VPR, a modified pU6 plasmid (U6 Fn scaf) was 
designed to enable cloning of only the spacer sequence into a plasmid, such that the 
Fn direct repeat was already present immediately downstream of the hU6 promoter 
(Figure 4.6B). This was achieved by digesting the U6 no scaf vector with Bpi1 and 
incorporating the Fn direct repeat immediately downstream of the hU6 promoter, whilst 
incorporating two new Bpi1 sites between the direct repeat and the terminator sequence. 
Two oligos (Fn DR F + Fn DR R) were annealed and ligated into the digested and gel 
extracted BpiI linearised U6 no scaf vector. 
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To assemble the three crRNAs targeting ASCL1 and IL1RN, oligos (Table 4.2) were designed 
to generate the spacer sequences and annealed together (Table 2.1), before ligating into 
the Bpi1 digested pU6 Fn direct repeat plasmid. After sequence verification, these crRNAs 
(all three crRNAs in a single sample or individually) were transfected alongside dFnCas12a-
VPR into HEK293 cells either pooled or individually. dFnCas12a-VPR without a targeting 
crRNA served as negative control. Three days post transfection, total RNA was extracted 
from each sample and 1µg was used to synthesize cDNA using oligo dT(20) primers (further 
described in chapter 6). 1ul of the generated cDNA was used for qRT-PCR analysis of the 
target gene and normalised to reference gene GAPDH. When performing a simple ANOVA 
with Tukey’s multiple comparisons test, we observed that a single crRNA was sufficient to 
enable transactivation for both endogenous genes (P = 0.02 for A2 and P = 0.006 for I2) 
(Figure 4.6C).  
 
Table 4.2 - ASCL1 and IL1RN crRNA oligos 
Oligo name Oligo sequence 
ASCL1 c1 F AGATAGCTGGGTTTGTTGTTGCAG 
ASCL1 c1 R AAACCTGCAACAACAAACCCAGCT 
ASCL1 c2 F AGATCAAGGAGCGGGAGAAAGGAA 
ASCL1 c2 R AAACTTCCTTTCTCCCGCTCCTTG 
ASCL1 c3 F AGATGGGAGTGGGTGGGAGGAAGA 
ASCL1 c3 R AAACTCTTCCTCCCACCCACTCCC 
IL1RN c1 F AGATCGCAGATAAGAACCAGTTTG 
IL1RN c1 R AAACCAAACTGGTTCTTATCTGCG 
IL1RN c2 F AGATCAGGAGGGTGACTCAGGCTA 
IL1RN c2 R AAACTAGCCTGAGTCACCCTCCTG 
IL1RN c3 F AGATGCATCAAGTCAGCCATCAGC 




Figure 4-6 - Screening activity of individual crRNAs against endogenous genes 
A) Diagrammatic representation of the targeting of dFnCas12a-VPR to endogenous promoters in 
HEK293 cells. Three crRNAs were designed to target a ‘TTV’ PAM sequence between 50 and 300bp 
upstream of the transcription start site for both ASCL1 and IL1RN. The transcription start site was 
predicted using CAGE-Seq data curated by the FANTOM5 project. B) Cloning strategy for generating 
U6 Fn scaf vector. The U6 vector was linearised using BpiI, before ligating with annealed oligos 
encoding the Fn crRNA direct repeat and new BpiI sites for subsequent cloning. C) The crRNAs for 
each gene were transfected individually or as a pool alongside dFnCas12a-VPR into HEK293 cells. 
Graphs show qRT-PCR data for relative expression of the ASCL1 or IL1RN transcripts, with 
dFnCas12a-VPR only (dFV only) serving as a negative control, with the mean for the negative control 

















































Screening for ASCL1 transactivation

































Screening for IL1RN transactivation

















4.6 Identifying multiple active crRNAs targeting 3 genes 
Having demonstrated robust transactivation could be achieved with a single crRNA, we 
sought to identify two or more active crRNAs across three different genes. This would 
enable a number of subsequent experiments and analysis to be performed, allowing the 
exploration of the hypothesis that additive or synergistic up-regulation can be achieved 
when targeting multiple active crRNAs to a single promoter. We chose HBB as a third gene 
to target, as we had previously observed robust transactivation could be achieved when 
targeting its promoter with dFnCas12a-VPR (Figure 4.5B). As previously we had been able 
to identify an active crRNA when screening three unique crRNAs, for targeting both the 
ASCL1 and IL1RN promoter regions, we screened 6 crRNAs for each of the three promoters 
(Figure 4.7A), expecting at least 2 active crRNAs to be identified for each promoter. As 
three crRNAs were already available for targeting ASCL1 and IL1RN, a further three crRNAs 
were designed using the previously described design constraints. Six unique crRNAs were 
also designed for the targeting of the HBB promoter, employing the same design 
constraints (Figure 4.7A). The crRNAs were generated (Table 4.3) as described, by 
annealing oligos and ligating into BpiI digested pU6 Fn direct repeat plasmid (Materials and 
methods 2.1.1 and 2.1.2). After sequence verification, each of these crRNAs were 
individually transfected into HEK293 cells along with dFnCas12a-VPR. Three days after 









Table 4.3 - Oligos for generating ASCL1, HBB and IL1RN crRNAs 
Oligo name Oligo sequence 
Fn HBB g1 F 2 CACCGTAATTTCTACTGTTGTAGATTACTGATGGTATGGGGCCAA 
Fn HBB g1 R 2 AAACTTGGCCCCATACCATCAGTAATCTACAACAGTAGAAATTAC 
Fn HBB g2 F 2 CACCGTAATTTCTACTGTTGTAGATAAGTCCAACTCCTAAGCCAG 
Fn HBB g2 R 2 AAACCTGGCTTAGGAGTTGGACTTATCTACAACAGTAGAAATTAC 
Fn HBB g3 F 2 CACCGTAATTTCTACTGTTGTAGATCAAGTGTATTTACGTAATAT 
Fn HBB g3 R 2 AAACATATTACGTAAATACACTTGATCTACAACAGTAGAAATTAC 
ASCL1 crRNA 4 
F AGATTTGTTGCAGTGCGTGCGCCT 
ASCL1 crRNA 4 
R AAACAGGCGCACGCACTGCAACAA 
ASCL1 crRNA 5 
F AGATtcccgCTCCTTGCAAACTCT 
ASCL1 crRNA 5 
R AAACAGAGTTTGCAAGGAGcggga 
ASCL1 crRNA 6 
F AGATctttctcccgCTCCTTGCAA 
ASCL1 crRNA 6 
R AAACTTGCAAGGAGcgggagaaag 
HBB crRNA 4 F AGATGTAGCAATTTGTACTGATGG 
HBB crRNA 4 R AAACCCATCAGTACAAATTGCTAC 
HBB crRNA 5 F AGATGAGGGAGGGCTGAGGGTTTG 
HBB crRNA 5 R AAACCAAACCCTCAGCCCTCCCTC 
IL1RN crRNA 4 
F AGATTCTGCATGTGACCTCCCATC 
IL1RN crRNA 4 
R AAACGATGGGAGGTCACATGCAGA 
IL1RN crRNA 5 
F AGATGTTTCTGCTAGCCTGAGTCA 
IL1RN crRNA 5 
R AAACTGACTCAGGCTAGCAGAAAC 
IL1RN crRNA 6 
F AGATGCCAGCATGAGGAGATGGGC 




When performing a simple ANOVA with Dunnett’s multiple comparisons test, identified 5 
crRNAs across the three different genes that displayed significant transactivation (Figure 
4.7B): A2 (P = 0.0003) for ASCL1; H1 (P = 0.003), H2 (P = 0.001), H4 (P = 0.03) for HBB and I2 
(P = 0.0002) for IL1RN. Two crRNAs A4 targeting ASCL1 and I5 targeting IL1RN may also 
possess some activity, however their activity was non-significant (P = 0.18 and P = 0.09 
respectively). Therefore, to determine combined activity of multiple crRNAs, the A2 + A4, I2 
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+ I5 and H1 + H2 pairs were chosen. We also screened the next most active crRNAs where 
the data suggested the potential for activity, including H4 + H5 and I4 + I6 into subsequent 
screening to determine whether crRNAs with low or non-significant activity would show 
enhanced or even synergistic activity upon co-transfection. 
 
 
Figure 4-7 - Identifying active crRNAs across multiple genes 
A) Diagrammatic representation of the targeting dFnCas12a-VPR to three endogenous promoters in 
HEK293 cells.  Alongside the 3 previously screened crRNAs targeting ASCL1 and IL1RN, 3 further 
crRNAs targeting the ‘TTV’ PAM sequence were designed and generated for each gene. 6 crRNAs 
were designed and generated for targeting the HBB promoter, following the same design constraints 
described for ASCL1 and IL1RN. B) The crRNAs for each gene were transfected individually with 
dFnCas12a-VPR into HEK293 cells. qRT-PCR analysis was performed on cells collected after 3 days 
incubation. Graphs show qRT-PCR data for relative expression of the ASCL1, HBB or IL1RN 
transcripts, with dFnCas12a-VPR delivered with a non-targeting crRNA serving as negative control (n 
= 3). The mean for each negative control was set to 1 and used to normalise the remaining 
samples.    
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4.7 Delivering crRNA pairs improves transactivation 
We used our crRNA pairs to screen for enhanced transactivation in HEK293 cells, compared 
to the individual crRNAs (Figure 4.8A). A non-targeting crRNA (the ‘alt PAM Fn Luc' crRNA 
sequence used for targeting the luciferase reporter vector in Figure 4.2) served as negative 
control. All crRNAs were co-transfected with dFnCas12a-VPR. Three days post transfection 
RNA was extracted, cDNA generated and qRT-PCR performed as previously described. 
When a Welch’s t test was performed to compare the activity of the crRNA pairs against 
the most active individual crRNA, for all three genes at least one of the pairs showed 
significantly higher activity than the most active single crRNA (Figure 4.8B).  A2 + A4 co-
transfected showed significantly higher transactivation than the most active individual 
crRNA - A2 (P = 0.001), H1 + H2 co-transfected showed significantly higher transactivation 
than the most active single crRNA - H2 (P = 0.02), and I4 + I6 showed significantly higher 
transactivation than the most active single crRNA - I6 (P = 0.02). An interesting anomaly 
was a non-significant (P = 0.12) reduction in activity observed when I2 + I5 were co-
delivered compared to the activity of I2 delivered alone. This result can be explained by the 
fact that the two crRNAs target opposite strands of the genome, with 12 nucleotides of 
overlap for the respective spacer sequences. This presents two models, the first being 
direct hybridisation between the crRNAs minimising the pool of active crRNAs available for 
targeting. The second model is based on competitive inhibition, as only one of two 
crRNA/dCas12a-VPR complexes can stably bind the DNA at any time, leading to the relative 
expression being lower than that observed for the most active single crRNA (I2). Contrary 
to our previous results, we also were able to see significant transactivation for I4 (P = 
0.003) and I6 (P = 0.002), which may in part be explained by the fact that previously one of 
the three repeats showed significantly lower transactivation across all samples (Figure 
4.7C) and when removed, significant transactivation was observed for both I4 (P = 0.02) 




Figure 4-8 - Screening activity of pooled vs. individual crRNAs 
A) Diagrammatic representation of the crRNAs used for targeting dFnCas12a-VPR to the ASCL1, HBB 
and IL1RN promoters. B) Graphs show qRT-PCR data for the relative expression of the ASCL1, HBB or 
IL1RN transcripts (n = 3). Two individual or pooled crRNAs were delivered to HEK293 cells alongside 
a non-targeting crRNA serving as negative control. The mean for each negative control was set to 1 

























































































































































































4.8 Screening pooled crRNA for synergy 
An important question when considering the delivery of multiple crRNAs to target 
multiple loci is whether a focus should be given to utilising multiple crRNAs to each 
promoter or to focus on single crRNAs for a wider range of target promoters. An 
important consideration is the level of impact observed when multiple active 
crRNAs are targeted to the same promoter, in particular whether we can observe a 
synergistic (greater than additive) increase to transactivation when more than one 
crRNA are delivered.  
  
 To assess for synergy we can compare the mean and standard deviation of the 
experimental result when both crRNAs were delivered to that of a hypothetical 
additive distribution. The hypothetical distribution can be inferred from the means 
and standard deviations of the experimental results when each crRNA is delivered 
separately. This would allow us to draw an accurate assessment of whether the 
experimental distribution we were sampling from was distinct from the 
hypothetical distribution and therefore whether synergy was observed (Figure 
5.1A).  
  
All statistics were performed using DDCt values, which are assumed to be normally 
distributed (as opposed to the actual fold change values, which are log-normally 
distributed due to the 2-(DDCt) transformation). The additive condition is defined as 
the sum of the log fold changes (or DDCt values) when the given crRNAs are 
introduced independently, compared to a non-targeting crRNA. The mean of the 
hypothetical additive distribution can be calculated by adding together the fold 
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changes observed for the each individual crRNA and taking log base 2 of this result. 
The variance could be calculated using the formula described in Materials and 
Methods 2.3.4, using the means and variances from the individual crRNA results. 
These calculated means and standard deviations for the hypothetical additive 
values for all 5 crRNA pairs were then used to test for significant separation 
compared to the results obtained experimentally when the crRNA pairs were co-
delivered. The results are also visually represented in Figure 5.1B.  
 
After calculating the means for the predicted additive distributions, we were able to 
see that the mean of the experimentally observed pooled conditions were higher 
than the mean of the hypothetical additive for 4 of the 5 crRNA pairs, with the only 
exception being the I2+I5 condition. 
 
To assess the significance of separation between the hypothetical additive 
distributions and experimentally observed pooled distributions, we used a Welch’s t 
test. For all 5 pairs tested, we observed no significant synergy; A 2+4 (P = 0.13) H 
1+2 (P = 0.1), H 4+5 (P = 0.17), I 2+5 (P = 0.09) and I 4+6 (P = 0.44). Graphs showing 
the DDCt values for the crRNA pairs are shown in (Figure 4.9B). The mean and 
standard deviation for the hypothetical distribution is plotted alongside the 





Figure 4-9 - Screening for synergistic activity of pooled crRNAs 
A) Diagrammatic representation of the generation of a hypothetical additive distribution from two 
individual experimentally derived distributions, alongside the subsequent comparison between the 
hypothetical additive condition and the experimental combined condition. B) Graphs showing the 
DDCt for the experimental individual and pooled crRNA conditions alongside the hypothetical 




























































































































































4.9 Conclusion and Discussion 
So far, we have demonstrated that synthetic transcription factors can be generated 
from Cas12a variants derived from three different species, confirming observations 
seen for dAsCas12a-VPR and dLbCas12a-VPR (Tak et al., 2017). We have presented 
a novel finding, demonstrate robust transactivation can be achieved by the 
dFnCas12a-VPR variant, which possesses the shortest described PAM sequence for 
the Cas12a family ‘TTV’ (Leenay et al., 2016). We have explored orthogonality 
between the three different dCas12a-VPR variants, observing evidence of 
orthogonality between dFnCas12a-VPR and dLbCas12a-VPR. Further 
characterisation of dFnCas12a-VPR for three different genes, showed that a single 
crRNA is sufficient to enable transactivation. 
 
Finally, we demonstrate that similar to results observed for Cas9-derived synthetic 
transcription factors (Maeder et al., 2013a), it is possible to observe greater 
transactivation of a target gene when multiple active crRNAs are delivered to target 
the same promoter. However, when testing for synergy, we do not observe 
significantly greater than additive transactivation.  
 
The desire for more targeting crRNAs to enable improved transactivation of 
individual genes, is naturally supported by the Cas12a system, as the Cas12a 
protein has been shown to process its own crRNA array (Fonfara et al., 2016). This 
means that longer crRNA arrays expressed from on a single transcript should in 
principle enable strong transactivation to be achieved for multiple genes, 
something we explore further in the subsequent chapter. 
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Work with Cas9 derived synthetic transcription factors (Maeder et al., 2013a), 
alongside more recent work with dLbCas12a-VPR (Tak et al., 2017) has shown that 
increased transactivation of targeted loci can be achieved when multiple synthetic 
transcription factors are targeted to the same loci. Work with dLbCas12a-VPR has 
also highlighted the capability of crRNA arrays to enable targeting of multiple crRNA 
to different loci from the same transcript. We wanted to test whether these 
observations were also seen for dFnCas12a-VPR. Furthermore, we wished to test 
the limitations of crRNA arrays, exploring the capacities of longer arrays. Finally, we 
sought to pursue novel applications of dFnCas12a-VPR, focussing on maximising the 
strengths of the highly dense targeting capabilities. To achieve this we built on 
previous work with Cas9, where variants of the wild-type Cas9 (Wright et al., 2015) 
and even a Cas9 based synthetic transcription factor (Zetsche et al., 2015c) were 
split into 2 fragments and shown to preserve activity when co-expressed. As such 
we sought to explore the generation of split dFnCas12a-VPR, to in particular enable 
AAV viral delivery, for future applications including gene therapy. 
 
5.2 Screening crRNA arrays for activity 
Having screened for activity of pooled crRNAs, we next explored the capacity of 
crRNA arrays to enable transactivation of target genes. We proceeded to design 
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and generate crRNA arrays for 4 of the 5 crRNA pairs previously screened (A 2+4, H 
1+2, H 4+5 and I 4+6). The crRNA arrays were designed to incorporate an extra 
direct repeat at the 3’ of the second crRNA to recapitulate the designs previously 
utilised by Tak et al (Figure 5.1A) (Tak et al., 2017). The crRNA arrays were 
generated by annealing and ligating three pairs of oligos into the digested pU6 no 
scaffold vector (Table 2.1) (Materials and Methods 2.1.1 and 2.1.2). After sequence 
verification, the constructed arrays were transfected into HEK293 cells as previously 
described, alongside the crRNAs pairs delivered together or individually. 
dFnCas12a-VPR delivered with a non-targeting crRNA was used as a negative 
control. 3 days post transfection, RNA was extracted, cDNA generated and qRT-PCR 
performed as previously described. The first key observation, was that all 4 crRNA 
arrays tested, across all three genes, showed highly significant transactivation 
compared to the negative control when a Tukey’s multiple comparisons test was 
performed; A array (2+4) (P < 0.0001), H array (1+2) (P < 0.0001), H array (4+5) (P < 
0.0001) and I array (4+6) (P = 0.005) (Figure 5.1B).  Of interest, we consistently saw 
across all arrays tested, that the mean for each array was higher than the mean for 
the pooled condition. However, when employing Tukey’s multiple comparisons test 
to compare the activity of the arrays to the crRNA pairs, only the HBB 4+5 array 
showed significantly higher activity than the corresponding crRNA pair (P = 0.02). 
Finally, we observed significantly higher transactivation for each array condition 
compared to the highest expressing individual crRNA for 2 of the 4 arrays tested; 




Figure 5-1 - Screening crRNA arrays for activity 
  A) Diagrammatic representation of the different constructs tested side by side in the subsequent 
qRT-PCR analysis. B) Graphs showing the fold change in expression of the three genes (ASCL1, HBB 
and IL1RN), comparing the array, combined crRNAs and individual crRNAs to the negative control 
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Comparing activity of 2X arrays 
to co-transfection and 
single crRNAs (HBB 4,5)
 99 
5.3 Screening crRNA arrays for synergy 
Having observed robust transactivation (Figure 5.2A) could be achieved using these 
short crRNA arrays, we next wished to test whether the arrays demonstrated 
synergistic transactivation. As described for testing synergy with pooled crRNAs, we 
calculated a ‘hypothetical additive distribution’ by combining means and variances 
of the two individual crRNA distributions as previously described (FIGURE 5.2A). To 
assess the significance of separation between the hypothetical additive 
distributions and experimentally observed array distributions, we used a Welch’s t 
test. Two of the arrays tested demonstrated synergistic transactivation; H12 array 
(H1 + H2) (P = 0.005) and H45 array (P = 0.005). Graphs showing the DDCt values for 
the crRNA pairs are shown in (Figure 5.2B). The mean and standard deviation for 
the hypothetical distribution is plotted alongside the experimental data for the 




Figure 5-2 - Screening for synergistic activity of crRNA arrays 
A) Diagrammatic representation of the generation of a hypothetical additive distribution from two 
individual experimentally derived distributions, alongside the subsequent comparison between the 
hypothetical additive condition and the experimental array condition. B) Graphs showing the DDCt 
for the experimental individual crRNA and array conditions alongside the hypothetical additive 





























































































































5.4 Screening 6-crRNA arrays for multiplexing 
Having observed that 2-crRNA arrays could enable robust transactivation of target 
genes, we next sought to test whether they could enable multiplexed 
transactivation within 6-crRNA arrays, with all three pairs being expressed from a 6-
crRNA array. We also sought to test whether there was a position dependent 
activity of the crRNA pairs depending on their position within the crRNA array. 
 
Six different 6-crRNA arrays were designed, such that the crRNAs in the first two 
positions would target one gene, the crRNAs in the next two positions would target 
a second gene and the crRNAs in the final two positions would target a third gene. 
The most active 2-crRNA arrays for ASCL1, HBB and IL1RN were utilised (A array 
(A2+A4), H12 array (H1+H2) and I46 array (I4 + I6)) (Figure 5.3A). All possible 
combinations were designed (Figure 5.3B). The 6-crRNA arrays were generated by 
annealing oligo pairs (Table 5.1) and ligating into a BpiI digested U6 vector 
(Materials and Methods 2.1.1 and 2.1.2). After sequence verification of the 
constructs, they were transfected alongside the following positive control 2-crRNA 
arrays; A array (A2+4), H12 array (H1+H2) and I46 array (I4+I6). A non-targeting 
crRNA served as a negative control. All the preceding constructs were delivered 
alongside dFnCas12a-VPR, with dFnCas12a-VPR delivered with a non-targeting 
crRNA serving as a negative control. Three days post transfection, RNA was 







Table 5.1 - Oligo pairs used for constructing 6x crRNA for multiplexing 
AHI array AIH array HAI array HIA array IAH array IHA array 
A2 first F A2 first F H1 first F H1 first F I4 first F I4 first F 
A2 first R A2 first R H1 first R H1 first R I4 first R I4 first R 
A24 F A24 F H1H2 F H1H2 F I4I6 F I4I6 F 
A24 R A24 R H1H2 R H1H2 R I4I6 R I4I6 R 
A4H1 F A4I4 F H2A2 F H2I4 F I6A2 F I6H1 F 
A4H1 R A4I4 R H2A2 R H2I4 R I6A2 R I6H1 R 
H1H2 F I4I6 F A24 F I4I6 F A24 F H1H2 F 
H1H2 R I4I6 R A24 R I4I6 R A24 R H1H2 R 
H2I4 F I6H1 F A4I4 F I6A2 F A4H1 F H2A2 F 
H2I4 R I6H1 R A4I4 R I6A2 R A4H1 R H2A2 R 
I4I6 F H1H2 F I4I6 F A24 F H1H2 F A24 F 
I4I6 R H1H2 R I4I6 R A24 R H1H2 R A24 R 
I6 last F H2 last F I6 last F A4 Last F H2 last F A4 Last F 
I6 last R H2 last R I6 last R A4 Last R H2 last R A4 Last R 
 (Refer to materials and methods section (Table 2.1) for sequence information.) 
 
The first key observation was that for all 6-crRNA arrays screened we observed 
highly significant transactivation above the negative control when Tukey’s multiple 
comparison test was performed for all three genes (P < 0.0001 for all arrays for all 
three genes) (Figure 5.3C). A second interesting observation was seen when 
comparing the positive controls to the arrays where their respective targeting 
crRNAs were in position 5 and 6. For all three genes, we saw that the positive 
control showed significantly higher activation than at least one of these two arrays. 
For ASCL1, when comparing the A array to IHA we observed a significantly lower 
activity for IHA (P = 0.02), for HBB when comparing the H12 array to AIH and IAH 
we also observed significantly lower activity for the 6-crRNA arrays (P = 0.02 and P = 
0.01 respectively). Finally, for IL1RN when comparing the I46 array to AHI and HAI 
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we also observed significantly lower activity for the 6-crRNA arrays (P = 0.0001 and 
P = 0.0002 respectively). These findings alongside the consistent visual downward 
trend observed when the fold activation of arrays were ordered by position of the 
active crRNAs within the 6-crRNA arrays (Figure 5.3B) led to the hypothesis that 
there may be a decrease in activity when crRNAs are in 3’ positions within longer 
arrays. 
 
To test this hypothesis, after ordering the cycle threshold results based upon the 
position of the targeting crRNAs within each array (e.g. AHI, AIH, HAI, IAH, HIA, IHA 
for ASCL1) a statistical test for linear trend was performed, with a significant 
downwards trend observed for ASCL1 (P = 0.0001), HBB (P = 0.001) and IL1RN (P < 
0.0001). When analysed together, the results observed for all three genes 
suggested that whilst active throughout the 6 crRNA array, crRNAs appeared to 






Figure 5-3 - Testing for multiplexing using 6x crRNA arrays 
A) Diagrammatic representation of the different positive control arrays. B) Diagrammatic 
representation of 6X crRNA arrays screened by qRT-PCR C) Graphs showing qRT-PCR data for the 
relative expression of ASCL1, HBB or IL1RN transcripts. The mean for the respective negative 
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5.5 Screening 6-crRNA array for position dependent activity of 
individual crRNA 
Having observed position dependent activity for crRNA pairs within a 6-crRNA array 
we next wanted to further dissect the role of position on crRNA activity. In 
particular we sought to test if this trend was also observed for individual crRNA 
targeting, by screening all possible positions of a single targeting crRNA within 6-
crRNA arrays. To test we generated a new set of 6-crRNA arrays, however this time 
only a single active crRNA ‘A2’, was present within the 6-crRNA arrays, with each of 
6 arrays to be screened having A2 in a different position (1 through 6). For the 
remaining 5 positions, non-targeting crRNA were incorporated (Figure 5.4A). The 
spacer sequences for these non-targeting crRNAs were designed by first generating 
20bp random DNA sequences using an online tool and subsequently performing 
nucleotide blast alignments against the human genome, selecting sequences where 
no perfect matches were observed. The 6-crRNA arrays were generated as 
previously described, annealing oligo pairs (Table 5.2) and ligating into a BpiI 
digested U6 vector (Materials and Methods 2.1.1 and 2.1.2). After sequence 
verification of the constructs, they were transfected alongside A array (A2 + 4) 
serving as a positive control. A non-targeting crRNA served as a negative control. All 
the preceding constructs were delivered alongside dFnCas12a-VPR. 3 days post 




The first key observation was that, as before each of the 6 crRNAs were able to 
show highly significant transactivation of ASCL1 when a Tukey’s multiple 
comparisons test was performed (P <  0.0001 for all 6-crRNA arrays) (Figure 5.4B). 
Furthermore we were also able to observe that when comparing the distributions 
for all 6 6-crRNA arrays, only Pos1 (active A2 crRNA in the most 5’ position) and 
Pos6 (active A2 crRNA in the most 3’ position) showed significant differences 
between one another, with the transactivation for Pos6 being significantly lower 
than Pos1 (P = 0.028). Finally, when performing a statistical test for linear trend, we 
were able to observe a significant negative trend as the active crRNA moved from 
the most 5’ position towards the most 3’ position of the array (P = 0.007). Taken 
together these results provide strong evidence for position dependent activity for 
6-crRNA arrays.  
 
Table 5.2 - Oligos used for constructing position dependent ASCL1 6x array 
Pos1 array Pos2 array Pos3 array Pos4 array Pos5 array Pos6 array 
A 1st 1 F NT 1st F NT 1st F NT 1st F NT 1st F NT 1st F 
A 1st 1 R NT 1st R NT 1st R NT 1st R NT 1st R NT 1st R 
A 1st 2 F A 2nd 1 F NT 12 F NT 12 F NT 12 F NT 12 F 
A 1st 2 R A 2nd 1 R NT 12 R NT 12 R NT 12 R NT 12 R 
NT 23 F A 2nd 2 F A 3rd 1 F NT 23 F NT 23 F NT 23 F 
NT 23 R A 2nd 2 R A 3rd 1 R NT 23 R NT 23 R NT 23 R 
NT 34 F NT 34 F A 3rd 2 F A 4th 1 F NT 34 F NT 34 F 
NT 34 R NT 34 R A 3rd 2 R A 4th 1 R NT 34 R NT 34 R 
NT 45 F NT 45 F NT 45 F A 4th 2 F A 5th 1 F NT 45 F 
NT 45 R NT 45 R NT 45 R A 4th 2 R A 5th 1 R NT 45 R 
NT 56 F NT 56 F NT 56 F NT 56 F A 5th 2 F A 6th 1 F 
NT 56 R NT 56 R NT 56 R NT 56 R A 5th 2 R A 6th 1 R 
NT last F NT last F NT last F NT last F NT last F A 6th 2 F 
NT last R NT last R NT last R NT last R NT last R A 6th 2 R 
 (Refer to materials and methods section (Table 2.1) for sequence information.) 
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Figure 5-4 - Testing for position dependent activity within 6x crRNA array 
A) Diagrammatic representation of the 6X crRNA arrays for screening for the impact of position on 
activity using qRT-PCR B) Graph showing qRT-PCR data for the relative expression of ASCL1 
transcripts. The mean for the negative control (dFV NT) was set to 1 and used to normalise the 
remaining samples (n = 3). 


















































5.6 Testing mutated direct repeat sequence for ameliorating position 
dependent activity 
As we had identified a position dependent effect for crRNA activity within crRNA 
arrays, we next wanted to ascertain the cause and look for strategies to prevent 
reduction in activity at the 3’ positions. One likely hypothesis included poor 
processivity of transcription, leading to premature termination of transcripts, which 
could potentially be explained by the presence of a premature transcriptional 
termination sequence within the crRNA array. We looked at the most relevant 
sequence that was consistently found in all arrays tested, the direct repeat, and 
observed that a non-canonical pol3 terminator sequence could be found (Orioli et 
al., 2011). When performing transcription analysis of non-canonical terminators, 
Orioli et al. screened the capacity of a number of putative terminators to induce 
premature termination of a transcript before a downstream canonical ‘TTTTT’ 
terminator sequence. Of particular interest they observed a ~5% reduction in read 
through of transcription for the sequence TTTCT compared to their negative control 
sequence ‘TTT’. As each of the 7 direct repeats within the 6-crRNA array possesses 
the ‘TTTCT’ sequence, the drop-off in activity may be due to the presence of this 
sequence, as studies have shown that activity of wild-type Cas12a has been shown 
to decrease as the concentration of crRNA decreases (Kallimasioti-Pazi et al., 2018).  
 
We sought to explore whether it would be possible to screen crRNA arrays that did 
not possess the non-canonical termination sequence TTTCT identified by Orioli et 
al. In their original work characterising Cas12a, Zetsche et al. had previously shown 
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using an in vitro cleavage assay that it was possible to mutate the sequence of the 
stem loop of the direct repeat, as long as base-pairing was preserved (Zetsche et al., 
2015a). Of particular interest, one of the mutation pairs they tested (mutating 
the 5th nucleotide from U to C and the 18th nucleotide from A to G) ablated the non-
canonical termination sequence but showed no observable reduction in cleavage 
activity.  
 
As such we proceeded to generate two new sets of arrays, one set which would 
utilise the original direct repeat and a second, using the same spacer sequences, 
but with mutated direct repeats, to remove the non-canonical termination 
sequence. 6 9-crRNA was designed for each set, where the most active single crRNA 
for Ascl1 (A2), HBB (H2) and IL1RN (I2) were incorporated at either the 1st, 5th or 9th 
position within the crRNA array, in all 6 possible combinations (AHI, AIH, HAI, HIA, 
IAH, IHA) (Figure 5.5A). This design would be expected to clearly show a stepwise 
reduction in activity for crRNAs at the 1st, 5th and 9th position, whilst also making it 
easier to observe when subsequent modifications successfully recover activity for 
crRNAs positioned towards the 3’ of the array. 
 
The remaining 6 positions within the array were occupied by non-targeting crRNAs 
generated as previously described. Finally, a positive control 3-crRNA array was 
made, using the original direct repeats, with A2 in position 1, H2 in position 2 and I2 
in position 3. This 3-crRNA array was expected to enable robust transactivation for 
all three genes to be targeted. The arrays were constructed as previously described, 
by annealing oligo pairs (Table 5.3) and ligating them into a BpiI digested U6 vector 
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(Materials and Methods 2.1.1 and 2.1.2). Due to challenges when cloning the 
constructs, a decision was made to proceed with only 5 of the 6 crRNA constructs, 
AHI, AIH, HAI, HIA, and IAH. After sequence verification, the 6-crRNA constructs 
possessing the original direct repeats were transfected into HEK293, alongside 
dFnCas12a-VPR, with dFnCas12a-VPR only serving as a negative control. Three days 
post transfection, RNA was extracted, cDNA generated and qRT-PCR performed as 
previously described. 
 
Table 5.3 - Oligos used for constructing 9-crRNA arrays with original direct repeat 
AHI O array AIH O array HAI O array HIA O array IAH O array 
Fn 1 A1 orig F Fn 1 A1 orig F Fn 1 H1 orig F Fn 1 H1 orig F Fn 1 I1 orig F 
Fn 1 A1 orig R Fn 1 A1 orig R Fn 1 H1 orig R Fn 1 H1 orig R Fn 1 I1 orig R 
Fn 2 A1 orig F Fn 2 A1 orig F Fn 2 H1 orig F Fn 2 H1 orig F Fn 2 I1 orig F 
Fn 2 A1 orig R Fn 2 A1 orig R Fn 2 H1 orig R Fn 2 H1 orig R Fn 2 I1 orig R 
Fn 3 1-2 orig F Fn 3 1-2 orig F Fn 3 1-2 orig F Fn 3 1-2 orig F Fn 3 1-2 orig F 
Fn 3 1-2 orig R Fn 3 1-2 orig R Fn 3 1-2 orig R Fn 3 1-2 orig R Fn 3 1-2 orig R 
Fn 4 2-3 orig F Fn 4 2-3 orig F Fn 4 2-3 orig F Fn 4 2-3 orig F Fn 4 2-3 orig F 
Fn 4 2-3 orig R Fn 4 2-3 orig R Fn 4 2-3 orig R Fn 4 2-3 orig R Fn 4 2-3 orig R 
Fn 5 H5 orig F Fn 5 I5 orig F Fn 5 A5 orig F Fn 5 I5 orig F Fn 5 A5 orig F 
Fn 5 H5 orig R Fn 5 I5 orig R Fn 5 A5 orig R Fn 5 I5 orig R Fn 5 A5 orig R 
Fn 6 H5 orig F Fn 6 I5 orig F Fn 6 A5 orig F Fn 6 I5 orig F Fn 6 A5 orig F 
Fn 6 H5 orig R Fn 6 I5 orig R Fn 6 A5 orig R Fn 6 I5 orig R Fn 6 A5 orig R 
Fn 7 4-5 orig F Fn 7 4-5 orig F Fn 7 4-5 orig F Fn 7 4-5 orig F Fn 7 4-5 orig F 
Fn 7 4-5 orig R Fn 7 4-5 orig R Fn 7 4-5 orig R Fn 7 4-5 orig R Fn 7 4-5 orig R 
Fn 8 5-6 orig F Fn 8 5-6 orig F Fn 8 5-6 orig F Fn 8 5-6 orig F Fn 8 5-6 orig F 
Fn 8 5-6 orig R Fn 8 5-6 orig R Fn 8 5-6 orig R Fn 8 5-6 orig R Fn 8 5-6 orig R 
Fn 9 I9 orig F Fn 9 H9 orig F Fn 9 I9 orig F Fn 9 A9 orig F Fn 9 H9 orig F 
Fn 9 I9 orig R Fn 9 H9 orig R Fn 9 I9 orig R Fn 9 A9 orig R Fn 9 H9 orig R 
Fn 10 I9 orig F Fn 10 H9 orig 
F 
Fn 10 I9 orig F Fn 10 A9 orig 
F 
Fn 10 H9 orig 
F 
Fn 10 I9 orig R Fn 10 H9 orig 
R 
Fn 10 I9 orig R Fn 10 A9 orig 
R 
Fn 10 H9 orig 
R 
 (Refer to materials and methods section (Table 2.1) for sequence information.) 
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We screened these arrays measuring the relative abundance of IL1RN transcript 
and as when testing the 6-crRNA arrays, we were able to see robust transactivation 
for all crRNA arrays relative to the non-targeting negative control (Figure 5.5B). As 
observed with the 6-crRNA array we also saw a significant trend for diminished 
activity when the IL1RN crRNA was positioned closer to the 3’ of the crRNA array (P 
=  0.0001).  
 
Figure 5-5 - Generating and screening 9x crRNA arrays [original Fn direct repeats] 
A) Diagrammatic representation of the 9X crRNA arrays utilising the original Fn direct repeat 
sequences.  B) Graph showing qRT-PCR data for the relative expression of IL1RN transcripts. The 
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We proceeded to clone crRNA arrays that were identical in design to the arrays just 
tested, with the exception that all direct repeats were mutated to ablate the non-
canonical terminator sequence (Figure 5.6A), replacing the 5th nucleotide in the 
direct repeat with a ‘C’ and the 18th nucleotide in the direct repeat with a ‘G’. These 
arrays were generated as previously described utilising annealed oligos which were 
ligated into a BpiI digested U6 vector plasmid. After the constructs were sequence 
verified, the relative abundance of IL1RN was screened for the 9-crRNA arrays 
possessing the mutated direct repeats. No significant increase in relative expression 
was observed for any of the crRNA arrays tested, with the exception of the positive 
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Figure 5-6 - Generating and screening 9x crRNA arrays [mutated Fn direct repeats] 
A) Diagrammatic representation of the 9X crRNA arrays utilising mutated Fn direct repeat 
sequences. Stars signify reciprocal mutation in the stem loop of the 5th and 18th nucleotides.  B) 
Graph showing qRT-PCR data for the relative expression of IL1RN transcripts. The mean for the 





















5.7 Generating split dFnCas12a-VPR 
One of the key future applications of synthetic transcription factors is for gene 
therapies. Whilst it has been shown that both Cas9 and Cas12a based synthetic 
transcription factors can be delivered to human cells outside of the body, when 
considering gene therapies in vivo, delivery becomes more challenging. Adeno-
associated viruses (AAV) offer one of the most attractive delivery vehicles, showing 
exceptionally low immunogenicity. However, AAV viruses also provide highly 
restrictive size constraints, being able to package only 4.4Kb of genetic material. 
This means delivery of the dFnCas12a-VPR constructs at their current size (~5.6Kb) 
would be impossible. One strategy to address this problem stems from work with 
Cas9, where researchers have shown it is possible to split Cas9 into 2 pieces 
(Zetsche et al., 2015c) which still show cleavage activity. Further work also showed 
it was possible to split a dCas9-VP64 synthetic transcription factor into two parts, 
and by fusing an FRB domain to the 1st half and FKBP domain to the 2nd half they 
were able to see robust transactivation when the two halves were expressed from 
different plasmids (Zetsche et al., 2015c). As such we aimed to test whether it was 
possible to see any transactivation when split dFnCas12a-VPR halves were 
expressed from different plasmids. 4 split variants of dFnCas12a-VPR were designed 
(Figure 5.7A), with the split sites being rationally selected. The split sites were 
chosen to be close to the middle of the coding sequence, whilst lying within an 
exposed loop of the protein (shown in Figure 5.7B) as previous work has shown that 





Figure 5-7 - Design of split dFnCas12a-VPR variants 
A) Diagrammatic representation of the positions of the 4 different split sites with full length 
dFnCas12a-VPR. The numbers highlight the amino acid position within the coding sequence. B) 
Image showing the protein visualisation of wild-type FnCas12a. The arrows highlight the positions of 














As a first step, to facilitate the library generation. We designed and generated an 
acceptor plasmid, where two Esp3I restriction sites were present immediately 
downstream of a CmV promoter and immediately upstream of a bGH terminator. 
This was achieved by digesting the FnCas12a original plasmid using Kpn1 and Xho1 
to remove the coding sequence between the CmV promoter and bGH terminator. 
The plasmid was then repaired with annealed oligos that incorporated two Esp3I 
restriction sites, to facilitate subsequent cloning of split dFnCas12a-VPR coding 
sequences (Figure 5.8A). This enabled the generation of all subsequent ‘halves’ by 
PCR amplification of the corresponding region of the full length dFnCas12a-VPR, 
with the primers designed to flank the amplified sequences with BpiI sites and 
include a stop codon at the ends of the amplified coding sequence for the first 
halves and a start codon before the amplified coding sequence for the second 
halves. PCR amplification from the dFnCas12a-VPR plasmid was performed and for 
all 8 fragments. The PCR reactions were subsequently column purified and BpiI 
digested before a second PCR purification was carried out to remove the unwanted 
digested fragments at either ends of the PCR products. These digested amplicons 
were subsequently ligated into the Esp3I digested ‘CmV Esp3I Ter’ acceptor vector 
(Materials and Methods 2.1.9 and 2.1.2) (Figure 5.8B). After sequence verification 
of the 8 constructs, they were transfected into HEK293 cells alongside the full 
length dFnCas12a-VPR.  
 
The screen was set up such that either the first half plasmid, the second half 
plasmid or both halves were transfected. For the positive control (full length 
dFnCas12a-VPR) and all test conditions the single crRNA ‘H1’ was also delivered. 
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The full length dFnCas12a-VPR without a targeting crRNA served as a negative 
control. Three days post transfection, RNA was extracted, cDNA generated and qRT-
PCR performed as previously described (Materials and Methods 2.3.2). 
 
Figure 5-8 - Cloning of split dFnCas12a-VPR variants 
A) Diagrammatic representation of cloning strategy for generating the CmV Esp3I Ter vector for 
receiving split dFnCas12a-VPR fragments B) Diagrammatic representation of cloning strategy for 
generating the split dFnCas12a-VPR plasmids. A) Graphs showing the qRT-PCR data for the full 
length dFnCas12a-VPR delivered with the H1 crRNA serving a positive control and the full length 
dFnCas12a-VPR without a targeting crRNA served as a normalising negative control (n = 2). The first 














Digestion with KpnI and XhoI 



















































An ordinary one-way ANOVA test was performed, with a subsequent Tukey’s 
multiple comparisons test showing that with the exception of the full length 
dFnCas12a-VPR positive control, only the condition with both split halves present 
for the split at position 2 and the split at position 4 showed significant 
transactivation above the dFnCas12a-VPR only negative control (P = 0.04 and P = 
0.0003 respectively). Furthermore, when comparing the conditions where both 
halves were delivered compared to either the first half or the second half, only the 
split at position 4 showed significantly greater activation than if either half was 
independently delivered (P = 0.03 and P = 0.03 respectively). These results are 
visually represented in Figure 5.9. 
 
 
Figure 5-9 - Screening split dFnCas12a-VPR variants 
qRT-PCR data for the full length dFnCas12a-VPR delivered with the H1 crRNA serving a positive 
control and the full length dFnCas12a-VPR without a targeting crRNA served as a normalising 
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5.8 Generating synthetic chromatin editors  
CRISPR based synthetic chromatin editors, as previously discussed in chapter 1, are 
chromatin modifying effector domains, recruited by dCas9 to a target locus to 
enable the laying or removal of a specific epigenetic mark. This enables a more 
directly related analysis of causality when compared to chemical approaches for 
epigenetic modification, where global changes are observed. In the following work 
we looked to generate novel synthetic chromatin editors, aiming to lay a 
trimethylation mark at histone 3, lysine 36 (H3K36me3). This mark has typically 
been associated with heterochromatin and repression of promoters, however of 
interest, work by Luco et al. demonstrated that through overexpression of SETD2, 
they were able to observe not only increased laying of the H3K36me3 mark, but 
furthermore significantly altered exon inclusion rates for polypyrimidine tract–
binding protein dependent exons (Luco et al., 2010). Suggesting there may be a 
direct causality between the laying of the H3K36me3 and alternative splicing. To 
explore this relationship, we sought to generate a synthetic chromatin editor that 
was able to lay the H3K36me3 mark at specific loci. To achieve this, the catalytic 
core of SETD2 (Yang et al., 2016) was amplified from a GFP-SETD2 plasmid 
(Carvalho et al., 2014) using SETD2 F + SETD2 R (Table 2.1). The PCR was 
subsequently ran on a 1% agarose gel and the amplicon was gel extracted. Next the 
dcas9-VPR plasmid (addgene #63798) (Table 2.2) was digested with BsrGI to release 
the VPR domain. After incubation the digestion was run on an agarose gel and the 
plasmid backbone was gel extracted and purified. Finally the purified backbone and 
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the SETD2 core amplicon were assembled using Gibson assembly (Figure 5.10A) 
(Materials and Methods 2.1.13). 
 
We also designed and generated a dCas9-SETD1A synthetic chromatin editor, as 
SETD1A has been shown to be responsible for mono, bi and tri-methylation of 
histone 3, lysine 4 (H3K4) (Lee and Skalnik, 2005). A correlation between the 
H3K4me3 and alternative splicing has been observed, with suppression of H3K4me3 
through ASH2L knockdown impacting splicing patterns and suppression of splicing 
attenuating H3K4me3 (Davie et al., 2015). A putative catalytic core of SETD1A was 
chosen, including the set domain as well as the adjacent CFP1 interacting domain, 
shown to be important for SETD1A activity (Lee and Skalnik, 2008). 
 
The dCas9-SETD1A was generated by ordering a gblock (IDT) encoding the SETD1A 
core domain. This was subsequently PCR amplified using SETD1A F + SETD1A R 
(Table 2.1).  The dCas9-VPR plasmid was digested with BsrGI to release the VPR 
domain. After incubation the digestion was run on an agarose gel and the plasmid 
backbone was gel extracted and purified. Gibson assembly was performed, using 
the linearised plasmid backbone and the SETD1A core amplicon to generate the 
dCas9-SETD1A plasmid (Figure 5.10A).  
 
After sequence verification, dCas9-SETD2, dCas9-SETD1A and dCas9-VPR were 
transfected into HEK293 cells. The transiently transfected cells were incubated for 2 
days at 37°C and 5% CO2, before being washed with PBS and resuspended in SDS-
PAGE sample buffer for Western Blot analysis using an anti Cas9 polyclonal 
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antibody (Clontech GuideIT, 632607) (1:3000) (Materials and Methods 2.1.14). The 
proteins could then be visualised alongside the Beta actin loading control, after 
secondary incubation with anti-rabbit HRP antibody and HRP conjugated anti-beta-





Figure 5-10 - Cloning and screening for expression of putative synthetic chromatin editors  
A) Diagrammatic representation of cloning strategy for generating the putative synthetic 
transcription factors dCas9-SETD2 and dCas9-SETD1A B) Western blot showing the expression of 
dCas9-SETD1A, dCas9-SETD2 and dCas9-VPR in HEK293 cells. 
 
SETD1A
1 = dCas9-SETD1A (202.5 kDa)
2 = dCas9-SETD2 (199.7 kDa)
3 = dCas9-VPR (225 kDa)
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After showing that the putative synthetic transcription factors successfully 
expressed in mammalian cells, we proceeded to establish a ChIP-qPCR protocol 
(described in greater detail in chapter 2), to enable identification of differences in 
deposition of a mark at the target loci. In the first stage of this assay, chromatin is 
crosslinked using formaldehyde, to preserve the interaction between histones and 
target DNA over the subsequent steps. After crosslinking, the cells are sonicated, to 
produce chromatin fragments. At this stage a quality control step is performed, 
with the ideal shearing pattern to lie between 200bp and 500bp (Figure 5.11A), to 
provide high resolution without significant disruption of nucleosomes. If the 
chromatin is of sufficient quality and size, then immunoprecipitation is performed 
to enable preferential enrichment of loci crosslinked with histones possessing the 
mark of interest. Finally, the enriched chromatin can be purified alongside un-
enriched chromatin and qPCR can be performed to screen for changes of 
abundance at a loci of interest or preferential enrichment of two or more targets. 
With the help of a colleague at the Buonomo lab, we screened for enriched histone 
3 lysine 27 acetylation at a positive control locus (TSIX), relative to a negative 
control loci (X5) (previously validated by our collaborator) (Table 2.3). We were 
subsequently able to observe a highly significant enrichment for the TSIX locus (P = 
0.002) (Figure 5.11B), establishing the ChIP qPCR protocol as a viable screening 









Figure 5-11 - Establishing ChIP-qPCR protocol 
A) Sonicated mouse embryonic stem cell chromatin ran on a 1% agarose gel B) Graph showing qRT-
PCR results, for the relative enrichment of target loci after H3K27ac enrichment of chromatin (n = 3). 
The ratio of the abundance of each loci in the enriched chromatin fraction compared to an 
































   
5.9 Conclusion and Discussion 
In the preceding chapter we have explored synergy, observing significant synergy 
occurring for two of the four crRNA arrays tested, but not when delivering the 
crRNA pairs expressed from separate plasmids. This discrepancy may in part be due 
to the fact that the pooled crRNAs were delivered on separate plasmids, whereas 
each array was expressed from a single plasmid. As transfection efficiencies are 
below 100% a lower percentage of cells can expect to receive both crRNA plasmids 
at the same time (pooled condition) compared to a single plasmid and as such any 
synergistic impact cause by co-delivery of separate plasmids will be reduced. 
  
We also explore the capabilities of crRNA arrays to enable transactivation for 
dFnCas12a-VPR. We not only see robust activity for all arrays tested but can also 
observe multiplexed transactivation of three different genes from a single 6-crRNA 
array. We do however observe a significant drop in activity when crRNAs are 
positioned to the 3’ of longer crRNA arrays. We go on to explore a possible cause, 
the presence of a non-canonical pol3 termination sequence within the direct 
repeats of the crRNA arrays. However due to the lack of observable activity seen 
when the direct repeat is mutated (based upon results from Zetsche et al. who 
showed that in vitro cleavage was preserved with this specific reciprocal mutation), 
we chose not to pursue this further. In the future it would be interesting to explore 
if the same position dependent reduction in activity is observed when the crRNA 
array is expressed from a pol2 promoter. Whilst Campa et al. have recently shown 
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that long 20-crRNA arrays can be expressed from a pol2 transcript, they did not 
explore or otherwise observe position dependent activity within their arrays 
(Campa et al., 2019). 
 
We also provide evidence that split variants of dFnCas12a-VPR are able to induce 
transactivation when co-expressed in the same cells alongside a targeting crRNA. 
This capability opens up a number of applications for dFnCas12a-VPR, allowing 
delivery using AAV viruses (preferred for gene therapy due to low immunogenicity) 
and providing a substrate for layered logic gates, as both halves must be expressed 
to observe activity. 
 
Of note more work will need to be carried out to see if the same split ‘halves’ show 
significant transactivation when targeting alternative genes. Furthermore, the level 
of transactivation is severely diminished for the split variants relative to the full 
length dFnCas12a-VPR a key limitation that could be addressed either through the 
incorporation of dimerisation domains (Zetsche et al., 2015c) or inteins. Both the 
use of inteins and dimerisation domains have shown the capacity to recover activity 
close the full length proteins for split dCas9-VP64 and wild-type Cas9 respectively. 
 
Finally, whilst we generated and showed expression for putative synthetic 
chromatin editors and established a ChIP qPCR pipeline, we have yet to screen the 
putative synthetic chromatin editors for activity. In future work, these constructs 
would be screened using ChIP-qPCR and if active, the same pipeline can be used to 
test the effector domains tethered to the dFnCas12a scaffold. 
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Chapter 6 - Discussion 
 
In this body of work we set out with the aim of generating Cas12a derived synthetic 
transcription factors, with the subsequent aims of characterising and working 
towards applications. In chapter 3, we confirm work that was published during the 
project by Tak et al. (Tak et al., 2017), showing that dAsCas12a can be adapted as a 
synthetic transcription factor. However, we provided a further two novel findings, 
showing that transactivation for dAsCas12a could be achieved when the 
transactivation domain was tethered to the N-terminus of the protein. The fact that 
dAsCas12a is still able to bind and VPR can still transactivate when fused to the N-
terminus suggests that this may be the case for other effector domains. This 
information can inform design considerations, when there are concerns about 
misfolding of the fusion protein or inactivation of the effector domain. Whilst 
dCas9-VPR and dCas12a-VPR are screened side by side, targeting the same 
Luciferase vectors, it is challenging to draw meaningful comparison of their relative 
activity. There are a large number of factors known to be involved in gRNA activity 
for synthetic transcription factors; chromatin state, positioning relative to TSS, 
position of effector domain relative to the CRISPR scaffold, PAM sequence selected 
etc. (Gilbert et al., 2014). As such it becomes very challenging to perform a 
meaningful comparative screen of Cas9 derived synthetic transcription factors and 
Cas12a derived synthetic transcription factors. Meaningful analysis will only be 
possible when employing a large-scale screen, so that a number of factors can be 
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simultaneously explored, with sufficient data points to derive significant 
conclusions. 
 
In chapter 4 we also demonstrated the novel finding that FnCas12a can be adapted 
to produce a synthetic transcription factor. This variant was of special interest for 
two reasons, firstly, with the exception of the original characterisation by Zetsche 
et al. (Zetsche et al., 2015a), the Fn variant has been understudied due to original 
work by Zetsche et al. suggesting it was not able to cleave the mammalian genome. 
Secondly and of critical importance, the Fn variant was characterised to have a 
shorter PAM sequence ‘TTN’ than the As and Lb variants (‘TTTN’), that have been 
the primary focus of subsequent research. As previously described, this feature 
enables denser targeting of genomic loci, providing approximately 4 times as many 
potential binding sites. This in turn provides more opportunities and flexibility when 
considering applications where exact positioning is important (such as 
transactivation) or when considering targeting multiple different targets 
simultaneously, where the chances of finding an active crRNA for all loci will 
decrease as the targets being screened increases. 
 
In chapter 4 we also screened the C-terminally tagged dAsCas12a-VPR, dFnCas12a-
VPR and dLbCas12a-VPR variants side by side and observed that all 3 variants 
showed significant transactivation. We also tested the activity of the 3 different 
variants when delivered with their own crRNAs or crRNAs with direct repeat 
sequences derived from the remaining two variants to assess orthogonality. Whilst 
we observed high fidelity (minimal activity with non-native crRNAs) for dFnCas12a-
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VPR, we did not observe high fidelity for dAsCas12a-VPR, which induced significant 
transactivation when delivered with the Fn crRNA, nor dLbCas12a-VPR, as activity 
was just below significance (P = 0.051). 
 
Orthogonality provides the capacity to enact independent programs within a cell, 
for example allowing the capacity to transactivate one group of genes and 
simultaneously repress another group of genes. Possessing this level of control is 
vital when seeking to generate predictable synthetic circuits and is essential for 
applications such as the laying of epigenetic marks. Orthogonality between 
different chromatin editors means that you can be confident only the desired 
chromatin mark is being laid at desired loci when utilising multiple chromatin 
editors within the same cell.  
 
In chapter 4 we go on the show that dFnCas12a-VPR can transactivate 3 different 
target genes using a single crRNA per target. Of particular note, we were able to see 
significant transactivation when targeting the PAM sequences; ‘TTTA’ (H4 crRNA), 
‘TTTC’ (I2 crRNA) and ‘TTTG’ (A2, H1, H2), similar to observations seen for AsCas12a 
and LbCas12a (Kim et al., 2017). 
 
We go on to observe that improved activation of a target locus can be achieved 
when delivering multiple crRNA targeting a single gene, similar to results observed 
with dLbCas12a-VPR (Tak et al., 2017). At the conclusion of chapter 4 we 
demonstrate that dFnCas12a-VPR can enable transactivation when crRNA arrays 
are delivered, showcasing one of the main strengths of the Cas12a system relative 
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to Cas9, through the ability to process its own crRNA array for subsequent 
targeting. 
 
In chapter 5 we focus on characterisation. First addressing the question of synergy, 
defined as the capacity to induce greater transactivation than would be expected 
by adding together the transactivation observed for the individual crRNAs. 
Collaborating with a statistician, we sought to provide a realistic estimation of not 
only the mean of an additive distribution (simply calculated by adding the mean 
fold increases of the individual crRNAs) but also the variance of the hypothetical 
distribution. This contrasts to previous approaches where the hypothetical additive 
variance was not derived from the constituent activity of the individual crRNAs, but 
by assuming that the variance would be the same as the experimental combined 
condition (Tak et al., 2017). When assessing co-transfected crRNA pairs, we did not 
observe synergy, however when the crRNA pairs were expressed from a single array 
we did observe synergistic transactivation for two of the 4 arrays tested.  
 
We go on to further explore the capabilities of crRNA arrays, testing multiplexing, 
where we can observe significant transactivation for three different genes targeted 
from the same array. This is consistent with results observed for dLbCas12a-VPR 
(Tak et al., 2017). We also saw that significant transactivation could be achieved 
when using 9-crRNA arrays. However, for all 6-crRNA and 9-crRNA arrays tested, we 
could observe a clear drop in activity for crRNAs positioned towards the 3’ of the 
array. This is a very important consideration when utilising Cas12a derived synthetic 
transcription factors, which can be considered during experimental design. One 
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example would be placing less active crRNAs for genes that show weaker 
transactivation at the 5’ of an array and more active crRNAs for genes that show 
stronger transactivation at the 3’ of the array it will be possible to up-regulate all 
target genes. There are a number of possible reasons as to why this consistent drop 
in activity is observed. One possibility is that this is a problem unique to polymerase 
3 driven promoters, with premature termination being seen when the polymerase 
recognises a weak non-canonical termination sequence in the direct repeats of the 
crRNA array. We began to explore this phenomenon, by mutating the direct repeats 
within a longer array, mutating a non-canonical termination sequence identified by 
Orioli et al. (Orioli et al., 2011) ‘TTTCT’. The mutation was utilised 2 nucleotide 
substitutions in the direct repeat identified by Zetsche and colleagues (Zetsche et 
al., 2015a) to preserve cleavage activity of wild-type FnCas12a in vitro. Due to the 
complete loss of activity within the 9-crRNA array upon mutation, we decided not 
to further pursue this approach. 
 
Finally, we looked into generating split variants of dFnCas12a-VPR. This is especially 
important when considering applications of the synthetic transcription factor. In 
terms of synthetic biology research, by splitting the synthetic transcription factor 
into two parts and having the two proteins expressed by different promoters, it 
becomes possible to perform a number of logic operations. This can be achieved by 
controlling expression of either half, through presence/absence, inversions using 
recombinases or expressing from independent chemically inducible promoters.  
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Clinical trials for the use of wild-type Cas9 are already underway and for a subset of 
debilitating diseases this offers a potential solution to improve a patient’s 
condition. However, the induction of a double-stranded break at a target locus is 
quite a drastic solution, exerting stress/toxicity on cells and invariably elevating the 
risk of cancer through increased chromosomal re-arrangements. As such 
approaches that can manipulate the transcriptome without inducing a double 
strand break may offer broader therapeutic value. For example in cases where 
phenotypes can be improved by increasing expression of a gene that can partially 
or fully compensate for a non-functional gene (Perumbeti et al., 2009). However, 
CRISPR based synthetic transcription factors are often too large to package into the 
preferred viral delivery vector adeno-associated virus (AAV), which offers an ideal 
delivery vector due to the minimal immune response elicited. A key limitation 
however is the fact that AAV viruses are only able to package up to a maximum of 
4.4Kb, with decreased packaging efficiency observed when approaching this upper 
limit. This presents a key challenge for SpCas9 derived synthetic transcription 
factors as well as the Cas12a derived synthetic transcription factors characterised in 
the preceding work, with dFnCas12a-VPR being encoded by 5.6Kb of DNA.  
 
Whilst work with SaCas9-VP64 (Matharu et al., 2019) have demonstrated that by 
using a shorter CRISPR protein it is possible to see transactivation and 
improvements in mouse pathology in vivo, the group still only tested delivery of 
one gRNA at a time and delivered the gRNA using a second AAV virus. 
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Due to the fact that the dFnCas12a-VPR is 5.6Kb, we explored the generation of a 
split variant, where two halves of the full-length protein could be expressed as two 
different transcriptional units. This strategy was based upon work with the Cas9 
system, previously described in Chapter 1 and Chapter 5, multiple groups were able 
to show that wild-type Cas9 could be split into two or even three pieces and still 
enable cleavage. In particular work by Zetsche et al. demonstrated that dCas9-VP64 
could be split into two fragments (Zetsche et al., 2015c). Building upon this work, 
we demonstrate initial evidence that dFnCas12a-VPR can be split and expressed on 
different plasmids. Whilst more work will be carried out to confirm this is observed 
when targeting different genes, these initial results open up the potential to deliver 
a split dFnCas12a-VPR in vivo using AAV viruses. Recent work by Campa et al. 
showed that crRNA arrays can be expressed and processed from the same pol2 
transcript as AsCas12a (Campa et al., 2019), incorporating a triplex secondary 
structure between the AsCas12a stop site and the crRNA array to prevent transcript 
degradation. By utilising a triplex between the split dFnCas12a-VPR ‘halves’ driven 
by a CmV minimal promoter, there would remain more than 1Kb of packaging 
space for the crRNA array, which represents over 25 targeting crRNAs. This would 
provide the flexibility to target multiple crRNAs to individual promoters to increase 
transactivation. 
 
Ongoing work will also look to explore whether improvements in transactivation for 
split dFnCas12a-VPR can be achieved by incorporating split inteins (protein motifs 
that enable trans-splicing of two different polypeptides, forming a single protein) 
into the two halves. As the NpuN and SspC split intein pair are only 312 and 113 bp 
 135 
respectively (Stevens et al., 2016) this would still enable the system to be utilised 
for AAV delivery in vivo. 
 
Finally, one of the most complex layers of regulation within the cell is the 
epigenome, with chemical alterations of the chromatin enabling semi-heritable, 
often long-lasting alterations to nuclear architecture and transcriptional programs 
that can reshape the phenotype of a cell and its progenitors.  
 
Of note it can be exceptionally challenging to decouple transcriptional manipulation 
and epigenetic manipulation. The most obvious causal relationships are caused by 
the fact that increasing transcription from a locus can lead to opening of a locus, 
reducing nucleosome occupancy and hence the association of histone associated 
chromatin marks. It is also important to remember that the polymerase complex 
responsible for reverse transcribing pol2 genes, is able to not only read epigenetic 
marks as it processes, but can also lay these marks. As a result, by increasing the 
polymerase density at a locus a number of confounding effects can be expected to 
occur as speed and durations of interactions are all altered. Having said this, we 
already know that epigenetic modifications are very important in regulation, and as 
with many features of synthetic biology, there are some approaches for 
manipulation that can offer relatively clear cut phenotypes. For example, by 
recruiting a histone acetyl-transferase to an inactive distal enhancer, it is possible 
to acetylate the nearby histones and induce a euchromatic state (Hilton et al., 
2015), effectively re-activating the enhancer and enable subsequent activation of 
downstream genes and genetic programs. As the prices and technical challenges 
 136 
associated with epigenetic analysis decrease, it is our expectation that there will be 
increasing interest in diverse tools to generate specific, targeted modifications. 
Further we believe that with improved understanding and more powerful 
predictive software, there will be a demand for platforms, such as dFnCas12a, that 
are able to densely target diverse loci with relative ease. 
 
It is the author’s hope that through the generation, characterisation and efforts 
towards applications of dFnCas12a synthetic transcription factors, we have aided in 
expanding the tools available for cell biologists to explore fundamental questions. 
Further we hope these tools can help accelerate the acquisition of knowledge 
around the manipulation of transcriptional networks, providing the knowledgebase 
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